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About this series
EMCDDA Risk Assessments are publications 
examining the health and social risks of 
individual new psychoactive substances.
The Risk Assessment Report consists of an 
analysis of the scientific and law enforcement 
information available on the new psychoactive 
substance under scrutiny and the implications 
of placing it under control. It is the outcome 
of a meeting convened under the auspices of 
the EMCDDA Scientific Committee.
This process is part of a three-step procedure 
involving information exchange/early warning, 
risk assessment and decision-making in the 
framework of Council Decision 2005/387/JHA.
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I Foreword
This publication presents the data and findings of the risk assessment on MDMB-CHMICA 
(methyl 2-[[1-(cyclohexylmethyl)-1H-indole-3-carbonyl]amino]-3,3-dimethylbutanoate), 
carried out by the extended Scientific Committee of the EMCDDA on 22 July 2016.
The Risk Assessment Report, which was submitted to the European Commission and the 
Council of the European Union on 25 July 2016, examines the health and social risks of the 
drug, information on international trafficking and the involvement of organised crime, as 
well as a consideration of the potential implications of subjecting the drug to control 
measures. MDMB-CHMICA is the twelfth new psychoactive substance to be risk assessed 
under the terms of Council Decision 2005/387/JHA.
On the basis of the Risk Assessment Report — and on the initiative of the European 
Commission — on 27 February 2017, the Council decided that MDMB-CHMICA should be 
subject to control measures across the Member States. This decision was adopted in the 
final stage of the three-step process — early warning, risk assessment and control of new 
psychoactive substances — established by the Council Decision 2005/387/JHA. This 
legal framework allows the EU institutions and Member States to act on all new and 
potentially threatening narcotic and psychotropic drugs which appear on the European 
drug scene, with the EMCDDA and Europol, in collaboration with their respective networks 
playing a central role in the early detection of such substances as well as the harms 
caused by their use — information that underpins risk assessment, and, ultimately, 
decision making.
In this respect we would like to acknowledge the excellent work done by the networks of 
the EMCDDA and Europol, as well as those of the EMA — the Reitox national focal points, 
Europol national units and the national competent authorities responsible for medicinal 
products — who played an essential role in collecting and providing national data.
Finally, we would like to thank all the participants in the risk assessment process for the 
high quality of work carried out. The resulting report is a valuable contribution at European 
level, which gives clear support to political decision-making.
Professor Dr Gerhard Bühringer  
Chair, Scientific Committee of the EMCDDA
Alexis Goosdeel 
Director, EMCDDA
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| EMCDDA actions on monitoring and responding to new drugs
The EMCDDA has been assigned a key role in the detection and assessment of new drugs 
in the European Union under the terms of a Council Decision 2005/387/JHA on the 
information exchange, risk-assessment and control of new psychoactive substances.
It establishes a mechanism for the rapid exchange of information on new psychoactive 
substances and provides for an assessment of the risks associated with them in order to 
permit the measures applicable in the Member States for the control of narcotic and 
psychotropic substances to be applied also to new psychoactive substances.
The three-step process involves information exchange/early warning, risk assessment and 
decision-making (see below). More detailed information can be found in the section ‘Action 
on new drugs’ of the EMCDDA’s website: www.emcdda.europa.eu/activities/action-on-
new-drugs
Council Decision 2005/387/JHA of 10 May 2005 on the information exchange,
risk-assessment and control of new psychoactive substances:
I. Information exchange
Early-warning system (EWS) EMCDDA–Europol Joint Reports
III. Decision-making Council Decisions on control
II. Risk assessment EMCDDA Risk Assessments
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  EMCDDA–Europol Joint Report on MDMB-CHMICA 
(methyl 2-[[1-(cyclohexylmethyl)-1H-indole-3-carbonyl]
amino]-3,3-dimethylbutanoate) — a summary
EMCDDA–Europol Joint Report on a new psychoactive substance: methyl 
2-[[1-(cyclohexylmethyl)-1H-indole-3-carbonyl]amino]-3,3-dimethylbutanoate — in 
accordance with Article 5 of Council Decision 2005/387/JHA on the information 
exchange, risk assessment and control of new psychoactive substances
In February 2016, the EMCDDA and Europol examined the available information on a new 
psychoactive substance methyl 2-[[1-(cyclohexylmethyl)-1H-indole-3-carbonyl]amino]-3,3-
dimethylbutanoate, commonly known by the abbreviation ‘MDMB-CHMICA’, through a joint 
assessment based upon the following criteria: (1) the amount of the material seized; (2) 
evidence of organised crime involvement; (3) evidence of international trafficking; (4) 
analogy with better-studied compounds; (5) evidence of the potential for further (rapid) 
spread; and (6) evidence of cases of serious intoxication or fatalities.
The EMCDDA and Europol agreed that the information available on MDMB-CHMICA 
satisfied criteria 1, 3, 4, 5, 6. The two organisations therefore concluded that sufficient 
information has been accumulated to merit the production of a Joint Report on MDMB-
CHMICA as stipulated by Article 5.1 of the Decision. Accordingly, the NFPs, the Europol 
national units (ENUs), the EMA and the World Health Organization (WHO) were formally 
asked to provide the relevant information within six weeks from the date of the request, i.e. 
by 21 March 2016.
The resulting Joint Report on MDMB-CHMICA was submitted to the Council, the 
Commission and the EMA on 14 April 2016. The report concluded that the health and 
social risks, caused by the use of, the manufacture of, and traffic in MDMB-CHMICA, as 
well as the involvement of organised crime and possible consequences of control 
measures, could be thoroughly assessed through a risk assessment procedure as 
foreseen by Article 6 of Council Decision 2005/387/JHA.
The full text of the Joint Report can be found at: 
www.emcdda.europa.eu/publications/joint-reports/mdmb-chmica
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Risk Assessment Report on a new 
psychoactive substance: methyl 
2-[[1-(cyclohexylmethyl)-1H-indole- 
3-carbonyl]amino]-3,3-
dimethylbutanoate (MDMB-CHMICA)
I Introduction
This risk assessment report presents the summary 
findings and the conclusion of the risk assessment 
carried out by the extended Scientific Committee of the 
European Monitoring Centre for Drugs and Drug 
Addiction (EMCDDA) on the new psychoactive 
substance methyl 2-[[1-(cyclohexylmethyl)-1H-indole-3-
carbonyl]amino]-3,3-dimethylbutanoate, commonly 
abbreviated to MDMB-CHMICA. The report is intended 
for policy makers and decision makers in the institutions 
of the European Union.
The report has been prepared and drafted in accordance 
with the conceptual framework and the procedure set 
out in the risk assessment operating guidelines (1). It is 
written as a stand-alone document, which presents 
a summary of the information considered during the 
detailed analysis of the scientific and law enforcement 
data available at this time. The conclusion section of the 
report summarises the main issues addressed and 
reflects the opinions held by the members of the 
Scientific Committee. A list of the information resources 
considered by the Scientific Committee, including 
a detailed technical report on MDMB-CHMICA, is 
provided below.
The risk assessment has been undertaken in compliance 
with Article 6 of Council Decision 2005/387/JHA of 10 
May 2005 on the information exchange, risk assessment 
and control of new psychoactive substances (2) 
(hereafter ‘Council Decision’). The Council Decision 
establishes a mechanism for the rapid exchange of 
information on new psychoactive substances (hereafter 
(1) EMCDDA (2010), Risk assessment of new psychoactive substances: 
Operating guidelines, Publications Office of the European Union, 
Luxembourg. Available at: http://www.emcdda.europa.eu/html.cfm/
index100978EN.html
(2) OJ L 127, 20.5.2005, p. 32.
‘EU Early Warning System’ (3)) that may pose public 
health and social threats, including those related to the 
involvement of organised crime. Thus, it allows the 
institutions of the European Union and the Member 
States to act on all new narcotic and psychotropic 
substances (4) that appear on the European Union drug 
market. The Council Decision also provides for an 
assessment of the risks associated with these new 
psychoactive substances so that, if necessary, control 
measures can be applied in the Member States for 
narcotic and psychotropic substances (5).
MDMB-CHMICA was formally notified to the EMCDDA 
through the EU Early Warning System in September 
2014 by the Hungarian National Focal Point, in 
accordance with Article 4 of the Council Decision. The 
notification related to the seizure of 0.19 grams of green/
brown herbal product that was seized in August 2014 by 
police in Ács, Hungary. Following an assessment of the 
available information on MDMB-CHMICA, and in 
accordance with Article 5 of the Council Decision, on 14 
April 2016 the EMCDDA and Europol submitted a Joint 
(3) The information exchange mechanism laid down by the Council 
Decision is operationalized as the European Union Early Warning 
System on New Psychoactive Substances (‘EU Early Warning System’). 
It is operated by the EMCDDA and Europol in partnership with the 
Reitox National Focal Points and Europol National Units in the Member 
States, the European Commission, and the European Medicines 
Agency.
(4) According to the definition provided by the Council Decision, a ‘new 
psychoactive substance’ means a new narcotic drug or a new 
psychotropic drug in pure form or in a preparation; ‘new narcotic drug’ 
means a substance in pure form or in a preparation that has not been 
scheduled under the 1961 United Nations Single Convention on 
Narcotic Drugs, and that may pose a threat to public health 
comparable to the substances listed in Schedule I, II or IV; ‘new 
psychotropic drug’ means a substance in pure form or in a preparation 
that has not been scheduled under the 1971 United Nations 
Convention on Psychotropic Substances, and that may pose a threat 
to public health comparable to the substances listed in Schedule I, II, 
III or IV.
(5) In compliance with the provisions of the United Nations Single 
Convention on Narcotic Drugs of 1961 and the United Nations 
Convention on Psychotropic Substances of 1971.
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Report on MDMB-CHMICA (6) to the Council of the 
European Union, the European Commission, and the 
European Medicines Agency (EMA). Taking into account 
the conclusion of the Joint Report, and in accordance 
with Article 6 of the Council Decision on 26 May 2016, 
the Council formally requested that ‘the risk assessment 
should be carried out by the extended Scientific 
Committee of the EMCDDA and be submitted to the 
Commission and the Council within twelve weeks from 
the date of this notification’.
In accordance with Article 6.2, the meeting to assess the 
risks of MDMB-CHMICA was convened under the 
auspices of the Scientific Committee of the EMCDDA 
with the participation of four additional experts 
designated by the Director of the EMCDDA, acting on 
the advice of the Chairperson of the Scientific 
Committee, chosen from a panel proposed by Member 
States and approved by the Management Board of the 
EMCDDA. The additional experts were from scientific 
fields that were either not represented, or not sufficiently 
represented on the Scientific Committee, and whose 
contribution was necessary for a balanced and adequate 
assessment of the possible risks of MDMB-CHMICA, 
including health and social risks. A further four experts 
participated in the risk assessment: two experts from 
the Commission, one expert from Europol, and one 
expert from the European Medicines Agency (EMA). The 
meeting took place on 22 July 2016 at the EMCDDA in 
Lisbon. The risk assessment was carried out on the basis 
of information provided to the Scientific Committee by 
the Member States, the EMCDDA, Europol and the EMA. 
A list of the extended Scientific Committee, as well as 
the list of other participants attending the risk 
assessment meeting, is annexed to this report (Annex 2).
For the risk assessment, the extended Scientific 
Committee considered the following information 
resources:
 § Technical report on methyl 2-[[1-(cyclohexylmethyl)-
1H-indole-3-carbonyl]amino]-3,3-dimethylbutanoate 
(MDMB-CHMICA) (Annex 1);
 § EMCDDA–Europol Joint Report on a new 
psychoactive substance: methyl 
2-[[1-(cyclohexylmethyl)-1H-indole-3-carbonyl]
amino]-3,3-dimethylbutanoate (MDMB-CHMICA) (6);
 § Open source information including scientific articles, 
official reports, grey literature, internet drug 
discussion forums and related websites (hereafter 
‘user websites’);
(6) EMCDDA and Europol (2016), EMCDDA–Europol joint report on a new 
psychoactive substance: methyl 2-[[1-(cyclohexylmethyl)-1H-indole-3-
carbonyl]amino]-3,3-dimethylbutanoate (MDMB-CHMICA), EMCDDA, 
Lisbon. Available at: http://www.emcdda.europa.eu/publications/
joint-reports/mdmb-chmica
 § Additional information provided during the course of 
the risk assessment meeting by the participants;
 § The EMCDDA operating guidelines for the risk 
assessment of new psychoactive substances (1); and,
 § Council Decision 2005/387/JHA of 10 May 2005 on 
the information exchange, risk assessment and 
control of new psychoactive substances (2).
Finally, it is important to note that this risk assessment 
report contains a discussion of the available information 
on serious adverse events such as acute intoxications 
(typically presenting to hospital emergency 
departments) and deaths associated with MDMB-
CHMICA. Such information is critical to the identification 
of emerging toxicological problems associated with new 
psychoactive substances within the European Union. In 
this context, it is important to recognise that the 
capacity to detect, identify, and report these events 
differ both within and between Member States. In the 
past few years, programmes have been introduced in 
some Member States to strengthen these capacities. 
The EMCDDA’s toxicovigilance system, which 
constitutes a central component of the EU Early Warning 
System, has also been strengthened resulting in more 
information being available regarding serious adverse 
events associated with new psychoactive substances. 
Nonetheless, it is likely that these events remain under-
detected and under-reported.
I  Physical, chemical and pharmacological description
Methyl 2-[[1-(cyclohexylmethyl)-1H-indole-3-carbonyl]
amino]-3,3-dimethylbutanoate (MDMB-CHMICA) is an 
N-cyclohexylmethyl indole-3-carboxamide (Figure 1). 
This substance is classed as a synthetic cannabinoid 
receptor agonist, a chemically diverse group of 
substances also referred to as synthetic cannabinoids (7).
Synthetic cannabinoid receptor agonists are functionally 
similar to Δ9-tetrahydrocannabinol (THC), the major 
psychoactive principle of cannabis. Like THC, they bind 
to and activate the CB
1
 and CB
2
 cannabinoid receptors 
which form part of the endocannabinoid system — 
(7) For the purposes of monitoring within the framework of the EU Early 
Warning System, the term ‘synthetic cannabinoids’ is used to include: 
the large number of synthetic cannabinoid (CB1 and CB2) receptor 
agonists that have been detected on the European drug market; 
a much smaller number of allosteric modulators (such as Org 27569) 
that change the structure of the cannabinoid receptors leading to 
altered activity when a ligand binds to the receptors; and substances 
that act as inhibitors of fatty-acid amide hydrolase (FAAH), which is 
the enzyme responsible for breaking down the endocannabinoid 
anandamide (such as URB597). 
Risk Assessment Report
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a system that helps regulate a large number of 
physiological functions in the body such as behaviour, 
mood, pain, appetite, sleep, the immune system, and the 
cardiovascular system. Many synthetic cannabinoids 
were first developed to study the endocannabinoid 
system as well as to explore their potential as 
therapeutic agents to treat a number of diseases and 
their symptoms — such as neurodegenerative diseases, 
drug dependence, pain disorders, and cancer. However, 
among other limitations, it has so far often proved 
difficult to separate the desired medicinal properties 
from unwanted effects.
Since the mid-2000s, commercial ‘legal high’ products 
containing synthetic cannabinoid receptor agonists have 
been sold in Europe as ‘herbal smoking mixtures’ and 
marketed as ‘legal’ replacements for cannabis. Most of 
the synthetic cannabinoid receptor agonists that are 
used in these products are manufactured by chemical 
companies based in China. They are shipped as bulk 
powders to Europe using express mail and courier 
companies; larger amounts may be shipped by air or sea 
cargo. Once in Europe, the retail products are put 
together. The herbs Damiana (Turnera diffusa) and 
Lamiaceae (such as Melissa, Mentha and Thymus) are 
commonly used as the plant base for the smoking 
mixtures. The synthetic cannabinoid receptor agonists 
are mixed with or sprayed onto the plant material, on an 
large scale using solvents such as acetone or methanol 
to dissolve the powders; equipment like cement mixers 
are then used to mix the ingredients together. The 
mixture is then dried and packaged. They are then sold 
on the internet by ‘legal high’ retailers and in bricks-and-
mortar head shops under a large number of brand 
names. A common blanket name (or slang name) for 
these herbal smoking mixtures in Europe is ‘Spice’ — 
which is a reference to the most common brand name 
used for these types of products when they first 
appeared on the market.
Cannabinoid receptor agonists controlled under the 
1971 United Nations Convention on Psychotropic 
Substances (Schedule II) are: the major active principle 
of cannabis, delta-9-tetrahydrocannabinol (Δ9-THC) (8) 
and two aminoalkylindole synthetic cannabinoid 
receptor agonists: JWH-018 (9) and AM-2201 (10).
In its pure form MDMB-CHMICA is an odourless, white 
and crystalline solid. It is poorly soluble in water.
(8) And some of its named isomers and their stereochemical variants
(9) Naphthalen-1-yl(1-pentyl-1H-indol-3-yl)methanone 
(10) 1-(5-Fluoropentyl)-1H-indol-3-yl]-(naphthalen-1-yl)-methanone
FIGURE 1
The molecular structure, molecular formula and 
molecular mass of MDMB-CHMICA.
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Molecular weight: 384.5118 g/mol
Monoisotopic mass: 384.2413
Information provided from seizures and collected 
samples reported by the Member States have noted that 
MDMB-CHMICA is typically found added to herbal 
material and as a powder. In the former case this 
includes a large number of commercially-branded ‘legal 
high’ products. The detection of MDMB-CHMICA in liquid 
form, tablets or capsules has not been reported to the 
EMCDDA.
MDMB-CHMICA contains a stereogenic centre thus 
allowing for the existence of a pair of enantiomers, 
(S)-MDMB-CHMICA and (R)-MDMB-CHMICA (11). The 
limited information available suggests that MDMB-
CHMICA may be found in the European drug market as 
the (S) enantiomer, although it is not possible to exclude 
the presence of the (R) enantiomer.
The analytical identification of MDMB-CHMICA in 
physical and biological samples is possible using several 
analytical techniques (Annex 1). The availability of 
analytical reference material is important for correct 
identification and for facilitating the quantification of 
MDMB-CHMICA in physical and biological samples; 
such reference materials are commercially available.
| Route of administration and dosage
MDMB-CHMICA is typically administered by smoking 
a herbal mixture that is either from a ready-to-use 
commercial ‘legal high’ product, or, less commonly, that 
is self-prepared. Similar to herbal cannabis, the mixture 
is usually prepared for smoking as a hand-rolled 
(11) Enantiomers are pairs of molecules that are mirror images of each 
other and therefore not superimposable. Although they have the same 
two dimensional molecular structure, enantiomers can exhibit marked 
differences in biological activity including pharmacological effects.
Risk Assessment Report
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cigarette (‘joint’) but it may also be smoked in a pipe or 
‘bong’. Psychonaut-type users (12) also report preparing 
solutions of MDMB-CHMICA which are then inhaled 
using an e-cigarette or other vaporisation device; oral 
administration and rectal administration has also been 
reported by this group.
Typically the synthetic cannabinoid receptor agonists in 
commercial herbal mixtures are frequently changed and 
rarely declared on the packaging. Therefore it is 
reasonable to assume that many individuals exposed to 
MDMB-CHMICA will be unaware that they are using the 
substance. In addition these consumers will be unaware 
of the dose they are consuming.
Limited information from self-reported experiences of 
psychonaut-type users suggests that a range of doses 
(0.1–15 mg) may be used in respect to self-prepared 
preparations. Doses above 1 mg have been generally 
described as ‘strong’ or ‘very strong’.
| Pharmacology
Data on the pharmacodynamic effects of MDMB-
CHMICA are limited to very recent in vitro studies which 
have investigated the functional activity of the 
substance on the cannabinoid CB
1
 and CB
2
 receptors. 
These data show that the (S) enantiomer of MDMB-
CHMICA is a potent and full agonist at the CB
1
 receptor 
(i.e. activates the receptor), and is approximately 10 
times more potent than JWH-018 (which is a full agonist 
already under international control). (S)-MDMB-CHMICA 
has also been shown to be an agonist at the CB
2
 
receptor. MDMB-CHMICA has some selectivity for the 
CB
1
 receptor over the CB
2
 receptor.
No studies were identified that have investigated the 
pharmacodynamics of MDMB-CHMICA on other 
pharmacological targets.
Data on the pharmacokinetics of MDMB-CHMICA are 
limited to the identification of metabolites. So far, over 
30 metabolites of MDMB-CHMICA have been identified 
in humans. The four most abundant metabolites 
detected were either products of the mono-
hydroxylation of the cyclohexyl moiety or products of the 
hydrolysis of the carboxylic ester function with 
associated glucuronide conjugates. No studies were 
(12) Defined by O’Brien et al., (2015) as ‘individuals who are motivated by 
a desire to explore drug effects, to document and share drug 
experiences with like-minded individuals’. O’Brien, K., Chatwin, C., 
Jenkins, C., Measham, F. (2015), ‘New psychoactive substances and 
British drug policy: A view from the cyber-psychonauts’, Drugs: 
Education, Prevention and Policy, 22(3), pp. 217–223.
identified that have investigated the pharmacology of 
these metabolites.
Information from self-reported experiences on user 
websites typically suggest that time of onset from 
smoking a herbal mixture containing MDMB-CHMICA is 
around 1 minute, with the duration of effects lasting 
around 120 minutes. In some cases the effects were 
reported to last longer.
|  Interactions with other substances, medicines, and other forms of interactions
No studies were identified that have investigated the 
potential interactions of MDMB-CHMICA. Although no 
data exist at the moment, it is expected that the highly 
lipophilic MDMB-CHMICA is oxidatively metabolised by 
cytochrome P450 enzymes. If so, interaction with the 
metabolism of many drugs and medicines may occur.
| Psychological and behavioural effects
Information on the psychological and behavioural effects 
of MDMB-CHMICA are limited to data provided in 
serious adverse events reported to the EMCDDA and in 
the scientific literature, as well as self-reported 
experiences from user websites.
Some users report that the effects of smoking herbal 
mixtures containing MDMB-CHMICA are more 
pronounced in comparison to cannabis. A review of 36 
user experiences on user websites found that the most 
commonly self-reported effects were euphoria, visual 
hallucinations, anxiety, paranoia, amnesia, sense of 
doom, and auditory hallucinations (in decreasing order). 
Other effects that have been reported include: feeling of 
warmth, laughing, changes in mood, disorientation, 
confusion, lack of concentration, vertigo, agitation, fear/
panic, psychosis, dissociation, violent behaviour, 
aggression and ‘acute behavioural disturbances’. These 
are similar to psychological and behavioural effects 
reported for other synthetic cannabinoid receptor 
agonists. Many of the effects mentioned relate to 
neuropsychiatric symptoms.
| Legitimate uses
There is currently no indication that MDMB-CHMICA may 
be used, in Europe or elsewhere, for legitimate purposes 
aside from in scientific research and as analytical 
reference materials as a result of its appearance on the 
drug market.
Risk Assessment Report
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There are no reported uses of MDMB-CHMICA as 
a component in industrial, cosmetic or agricultural 
products. A search of the REACH registered substances 
database hosted by the European Chemicals Agency 
(ECHA) using the CAS Registry Number returned no 
results.
MDMB-CHMICA does not appear to have an established 
or acknowledged medical value or use (human or 
veterinary) in the European Union. There is no marketing 
authorisation (existing, ongoing or suspended) for 
MDMB-CHMICA in the European Union or in the Member 
States that responded to the information request by the 
EMA that was launched under Article 5 of the Council 
Decision (6). In addition, there is no information that 
MDMB-CHMICA is used for the manufacture of 
a medicinal product or an active pharmaceutical 
ingredient of a medicinal product in the European Union. 
It is important to note that the data collection is 
incomplete and some countries indicated that this 
information is unknown. It should also be noted that 
there is no European Union database on the synthetic 
routes of all registered medicinal products.
I  Chemical precursors that are used for the manufacture
There is some information regarding the chemical 
precursors and the synthetic routes used to 
manufacture MDMB-CHMICA that has been detected 
within the European Union.
Methods for the production of MDMB-CHMICA are 
documented in the scientific literature and extensively 
studied in an EU funded project. According to the 
synthetic routes described, potential precursors of 
MDMB-CHMICA are indole, indole-3-carboxylic acid, 
indole-3-carboxylic acid methyl ester, indole-3-
carbaldehyde, cyclohexylmethyl bromide and L-tert-
leucine methyl ester (for synthesis of the (S) 
enantiomer). (S)-L-tert-Leucine is widely used for the 
manufacture of antiviral medicines and is produced 
mainly in China in large quantities. This may explain the 
choice of this precursor for the synthesis of MDMB-
CHMICA and other related synthetic cannabinoids that 
have been reported to the EU Early Warning System.
I Health risks
| Individual health risks
The assessment of individual health risks includes 
consideration of the acute and chronic toxicity of 
MDMB-CHMICA, as well as its abuse liability and 
dependence potential. Similarities to, and, differences 
from, other chemically- or pharmacologically-related 
substances should also be considered.
It is important to note that when interpreting information 
from acute intoxications and deaths as well as 
information from user websites, individuals may have 
used other pharmacologically active substances in 
addition to MDMB-CHMICA. The presence of and/or 
interaction with other substances or pre-existing health 
conditions may account for some or all of the effects 
reported.
The mode of use of MDMB-CHMICA may involve the 
combined use of other drugs (either intentionally or 
unintentionally). MDMB-CHMICA may be encountered in 
combination with other substances in commercially 
branded ‘legal high’ products. Analyses of various seized 
products have shown that the composition of 
commercial ‘legal-high’ type products containing 
synthetic cannabinoids that are sold on the drug market 
can vary significantly over geographical areas and time. 
Therefore, the users are unlikely to be aware of the exact 
dose or substance(s) being ingested (by whatever route). 
This presents an inherent risk to the individual.
It should be noted that the manufacturing process used 
to make smoking mixtures can lead to an uneven 
distribution of the synthetic cannabinoid receptor 
agonists within the herbal material. Inter-package and 
intra-package content of synthetic cannabinoid receptor 
agonists may vary significantly resulting in different 
amounts of the active substance. This may result in 
some products containing ‘hot pockets’ where the 
cannabinoid is highly concentrated, leading to doses 
that increase the risk of acute toxicity.
| Acute toxicity
No non-clinical or clinical studies were identified that 
have investigated the acute toxicity of MDMB-CHMICA 
and/or its metabolites.
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Acute intoxications
Forty-two acute intoxications associated with MDMB-
CHMICA were reported to the EMCDDA by 7 Member 
States: Austria (7 cases), France (2), Germany (7), 
Poland (3), Spain (2), Sweden (10), and, the United 
Kingdom (11). These typically related to acute non-fatal 
presentations to hospital emergency departments. They 
occurred during 2014 and 2015. In 25 of the 42 cases, 
MDMB-CHMICA was analytically confirmed in one or 
more biological samples taken from the patient at or 
around the time of intoxication: Austria (7 cases), 
Germany (3), Sweden (6) and the United Kingdom (9). In 
the remaining 17 cases, MDMB-CHMICA was only 
detected in a sample of the product/drug used or 
thought to have been used by the patient; these cases 
are not discussed further. The discussion below 
therefore relates to the findings in the 25 cases which 
were analytically confirmed through biological samples.
Data on the seriousness of the intoxication were 
reported for 13 out of the 25 cases. The seriousness of 
the intoxication was classified as: life threatening in 8 
out of the 13 cases; non-life-threatening in 3 cases; and, 
‘requiring treatment in hospital’ for 2 cases.
Of the 25 cases, 17 (68%) were male; 6 (24%) were 
female; in 2 (8%) of the cases the gender of the patient 
was unknown. The mean age of the male cases for which 
an age was known was 26 years (median 21); for the 
female cases the mean age was 25 years (median 20). 
For all cases, the ages ranged between 15 and 50 years.
In 6 of the 25 cases, MDMB-CHMICA was the only 
substance identified in the biological samples taken 
from the patients. In the remaining 19 cases other 
substances were detected along with MDMB-CHMICA. 
Typically these were other cannabinoids (including THC 
and its metabolites) (17 out of 25 cases) and/or ethanol 
(6/25). Other substances that were detected included: 
methamphetamine (4/25); amphetamine (3/25); 
benzodiazepines (3/25); morphine (1/25); and, 
buprenorphine (1/25).
Information on the length of hospital stay (including 
treatment in the emergency room only) was available for 
9 out of 25 cases. The hospitalisation period varied 
between 3 hours to 24 hours (mean: 12 hours; median: 8 
hours).
Data on clinical features reported in the 25 cases were 
consistent with those associated with acute intoxication 
by MDMB-CHMICA that have been reported in the 
literature and with intoxications with other synthetic 
cannabinoid receptor agonists. Coma and 
unconsciousness were the most prevalent features, 
having been reported for 10 out of 25 cases. Other 
clinical features include: tachycardia (7 cases), syncope 
(6), hyperemesis and/or nausea (4), mydriasis (3), 
seizures and convulsions (2), bradycardia (2), 
somnolence (2), serotonin toxicity (2), urinary and faecal 
incontinence (1), respiratory acidosis (1) and metabolic 
acidosis (1). In 4 out of 25 cases the patients were 
described as exhibiting aggression and/or severe 
disturbance of behaviour, some of which resulted in 
police intervention and/or transfers to psychiatric units.
Data on the route of administration was available for 14 
out of 25 cases. In all of them, the substance was either 
smoked or presumed to have been smoked or inhaled. In 
8 cases MDMB-CHMICA was consumed as a herbal 
product (information not available for the other cases).
Data on the psychological and behavioural effects 
associated with MDMB-CHMICA, including 
neuropsychiatric symptoms are discussed in Section 2 
of this report.
Deaths
A total of 29 deaths associated with MDMB-CHMICA 
were reported by 5 Member States and Norway: 
Germany (5 cases), Hungary (3), Poland (1), Sweden (9), 
the United Kingdom (10), and Norway (1).
In 28 cases, MDMB-CHMICA was analytically confirmed 
in one or more biological samples taken from the 
decedents. In the remaining case, MDMB-CHMICA was 
only confirmed from a sample of the product/drug 
believed to have been consumed by the deceased; this 
case has not been considered further.
Of the 28 cases, 24 were male (85.7%), 3 were female 
(10.7%), and, the gender was not reported for one death 
(3.6 %). The decedents’ ages ranged from 17 to 52 years. 
The mean age of the male decedents was 32 years 
(median 33); the mean age of the female decedents was 
31 years (median 30). In 6 cases the deaths occurred in 
2014; 20 deaths occurred in 2015; and, 1 death occurred 
in 2016. The year of death was not known for 1 case.
Information regarding the circumstances of death was 
reported for 18 out of 28 cases. In 72% of those cases, 
the individuals were found comatose or dead (at home or 
outside). In at least 2 of these cases smoking mixtures 
and smoking paraphernalia were found next to the body.
In 12 deaths MDMB-CHMICA was reported either as the 
cause of death or as contributing to death (even in the 
Risk Assessment Report
RISK ASSESSMENTS | MDMB-CHMICA  
12/51
presence of other substances); in 3 of these deaths 
MDMB-CHMICA was the sole drug present. In 10 deaths 
MDMB-CHMICA may have contributed to death but 
other substances were present that may have been more 
toxicologically significant. An alternative cause of death 
was recorded in 4 cases. In the cases where other 
substances were found these included, alcohol, 
benzodiazepines, opiates/opioids, antipsychotics, 
anticonvulsants, antidepressants, and other new 
psychoactive substances including synthetic 
cannabinoids.
Ability to operate machinery and drive
The behavioural effects of MDMB-CHMICA may limit the 
ability to operate machinery and drive safely.
| Chronic toxicity
No studies were identified that investigated the chronic 
health effects of MDMB-CHMICA and/or its metabolites.
| Abuse liability and dependence potential
No studies were identified that have investigated the 
abuse liability and dependence potential of MDMB-
CHMICA in animals or in humans. In vitro data show that 
MDMB-CHMICA affects the same molecular target as 
THC (specifically the CB
1
 receptor), it is therefore 
reasonable to consider that MDMB-CHMICA may have 
an abuse liability and dependence potential, however 
demonstrating this would require additional data from 
experimental studies.
Data from user websites and serious adverse events 
suggest that MDMB-CHMICA may have an abuse 
liability.
A case series of 4 patients seeking medical treatment 
with withdrawal-like symptoms who had consumed 
MDMB-CHMICA has been reported. A small number of 
user experiences posted on user websites include 
apparent tolerance and withdrawal-like symptoms 
indicate that the substance may have dependence and 
abuse potential.
| Public health risks
The public health risks associated with MDMB-CHMICA 
may be categorised in terms of patterns of use (extent, 
frequency, route of administration, etc.); availability and 
quality of the drug; information, availability and levels of 
knowledge amongst users; and, negative health 
consequences. Detailed information, including data on 
sporadic versus chronic use, that allow for 
a determination of public health risks associated with 
MDMB-CHMICA are unavailable.
Extent, frequency, and patterns of use
The available data suggest that MDMB-CHMICA is sold 
typically as commercial branded ‘legal high’ products in 
head shops as well as on the Internet as a ‘legal’ 
replacement for cannabis. Similar to other synthetic 
cannabinoid receptor agonists, it is reasonable to 
assume that many individuals are unaware that they are 
consuming MDMB-CHMICA.
No surveys were identified that have investigated the 
prevalence of MDMB-CHMICA use in the general 
population or in specific user groups.
Information on the extent to which products containing 
synthetic cannabinoid receptor agonists are used is 
limited. From the information that is available, it would 
appear that the prevalence of their use in the general 
population is low in Europe. A number of surveys aimed 
at examining the prevalence of use of ‘Spice’-like 
products (13) have been launched but their coverage and 
representativeness remains limited.
In the United Kingdom last year, the reported lifetime use 
of ‘Spice’ in household surveys (age 16–64) was 0.2 % 
(2010/2011) and 0.1 % (2011/2012). In Spain, in 2012, 
a national survey on drug use among students (age 
14–18) also identified low levels of use of ‘Spice’ 
products, with prevalence rates of 1.4 % for lifetime use, 
1.0 % for last year use and 0.6 % for last month use, 
which indicated a small increase from the previous 
survey results from 2010 (1.1 %; 0.8 %; and 0.5 % 
respectively). In France in 2014 a survey of adults 
(18–64) with a question about the use of ‘synthetic 
cannabinoids’ reported lifetime use of 1.7 %. Another 
survey in France, among young people aged 17, reported 
that 1.7 % of them have previously used a synthetic 
cannabinoid. The German city of Frankfurt has studied 
the use of smoking mixtures and ‘Spice’ among students 
aged 15–18. They reported lifetime levels of use of 7 % in 
2009; 9 % in 2010; 7 % in 2011 and 2012; 5 % in 2013; 
and 6 % in 2014. Studies with non-probabilistic samples 
have identified higher levels of synthetic cannabinoid 
(13) ‘Spice’ is a common blanket name used for ‘legal high’ products 
containing synthetic cannabinoid receptor agonists (‘Physical, 
chemical and pharmacological description’).
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receptor agonist use than among the general population. 
The 2012 Global Drug Survey, for example, reported last 
year prevalence levels of 3.3 % among all respondents 
from the United Kingdom and 5.0 % among regular 
clubbers from the United Kingdom.
Availability and quality on the market
Since August 2014, when it was detected first in 
Hungary, MDMB-CHMICA has been detected in 23 
Member States (Austria, Belgium, Bulgaria, Croatia, 
Cyprus, Denmark, Estonia, Finland, France, Germany, 
Greece, Hungary, Latvia, Lithuania, Luxembourg, 
Netherlands, Poland, Romania, Slovenia, Spain, Sweden, 
Slovakia, and the United Kingdom), Turkey and Norway.
MDMB-CHMICA is sold online either as commercial 
‘legal high’ ‘herbal mixtures’ or as a powder. In 
commercial products it is usually not stated if the 
product contains MDMB-CHMICA or any other synthetic 
cannabinoid receptor agonist. Furthermore, Germany 
reported to Europol, that, in addition to being sold online, 
MDMB-CHMICA is well known among drug users and is 
often offered by drug dealers in addition to being 
available to purchase online.
Due to the high potency of some synthetic cannabinoid 
receptor agonists, the amount of powder needed for 
each packet can be in the order of a few tens of 
milligrams. This means that each kilogram of bulk 
powder may produce thousands of packets of ‘legal 
highs’ (Section 6). For example, 1 kg of powder can be 
used to produce 1 million doses each containing 1 mg of 
active substance.
Detailed information available with regards to route-
specific by-products produced during the synthesis of 
MDMB-CHMICA is currently not available. There are no 
quantitative data available on the impurities detected in 
seized and collected samples reported to the EMCDDA 
by the Member States.
The manufacturing process used to make smoking 
mixtures can lead to an uneven distribution of the 
synthetic cannabinoid receptor agonists within the 
herbal material. There is often a large variation in the 
amount of synthetic cannabinoid receptor agonists 
present both between different packages of products 
and within an individual product. This can result in some 
products containing large amounts of synthetic 
cannabinoid receptor agonists as well as ‘hot pockets’ 
where the cannabinoid is highly concentrated on certain 
parts of an individual product, leading to higher doses in 
that region increasing the risk of acute toxicity and 
outbreaks of mass poisonings. 
Characteristics and behaviour of users
Information on the characteristics and behaviour of 
users of MDMB-CHMICA is limited.
‘Legal high’ products containing MDMB-CHMICA are 
marketed as ‘legal’ replacements to cannabis. It is 
therefore likely that a range of different cannabis users 
would be interested in these products.
The available data suggests that MDMB-CHMICA is used 
by cannabis users including those who are regularly 
subjected to drug testing procedures such as prisoners. 
It is also used by psychonaut-type users.
In most cases, it appears that MDMB-CHMICA is not 
specifically sought after by users, who may purchase it 
unknowingly. Commercial branded ‘legal high’ products 
are known to be highly variable in terms of composition 
and dosage and therefore users are unlikely to know that 
they are consuming MDMB-CHMICA.
Nature and extent of health consequences
Data on the health consequences of MDMB-CHMICA 
are mostly limited to the acute intoxications and deaths 
which are discussed above.
Long-term consequences of use
There is no information on the long-term consequences 
of MDMB-CHMICA use.
Conditions under which the substance is obtained 
and used
There is limited data on the conditions which MDMB-
CHMICA is obtained and used.
Sources appear to include internet retailers, bricks-and-
mortar shops, friends and other acquaintances, as well 
as street-level drug dealers. The available data suggests 
that many users are likely to be unaware that they have 
sourced and used MDMB-CHMICA.
Based on the available data, and given that MDMB-
CHMICA is typically sold as a ‘legal’ replacement to 
cannabis, it seems reasonable to consider that MDMB-
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CHMICA will be used in the same environments as 
cannabis.
I Social risks
While there have been no studies of the effects of 
MDMB-CHMICA in animals or in humans, data from 
acute intoxications, deaths, and, self-reported user 
experiences, suggest that the acute behavioural effects 
of MDMB-CHMICA might, at least, bear some similarities 
to cannabis.
| Individual social risks
There is no information on whether the use of MDMB-
CHMICA affects education or career, family or other 
personal or social relationships, including 
marginalisation.
|  Possible effects on direct social environment (e.g. neglect of family, violence)
While there is no specific information on the possible 
effects of MDMB-CHMICA on the direct social 
environment, multiple reports have indicated 
a possibility for violence and aggression.
|  Possible effects on society as a whole (public order and safety, acquisitive crime)
While there is no specific information on the possible 
effects of MDMB-CHMICA on society as a whole, 
multiple reports have indicated a possibility for violence 
and aggression. In particular, concern was expressed 
with regard this in certain circumstances e.g. prisons 
and psychiatric institutions. In addition, the detection of 
MDMB-CHMICA in cases of suspected driving under the 
influence indicated a potential for a wider risk to public 
safety.
Data related to the social risk associated with the 
trafficking and distribution of MDMB-CHMICA is limited.
| Economic costs (demands on healthcare)
Due to the lack of data, it is not possible at this time to 
estimate whether MDMB-CHMICA is associated with 
greater healthcare costs than other drugs.
| Possible appeal to specific population groups
There is no detailed data on the possible appeal of 
MDMB-CHMICA to specific user groups. However, the 
available data suggests that those using MDMB-
CHMICA include: cannabis users; people who 
experiment with any drug that is new and readily 
available (such as ‘psychonauts’); and, by individuals 
who are subjected to drug testing procedures (including 
those in prison).
The extent of the possible appeal of synthetic 
cannabinoid receptor agonists to cannabis users may be 
compounded by different factors, as they are 
a heterogeneous group. They may include those wanting 
a ‘legal’ alternative to illicit drugs, or drug users wishing 
to pass successfully an employment/other drug testing 
procedure aimed at detecting illicit drug use. This may be 
an important issue for any setting where drug 
abstinence control is obligatory (e.g. specific psychiatry 
or prison settings, driving liability testing, etc.).
Overall, the extent of the possible appeal of MDMB-
CHMICA to users is unknown.
I  Information on manufacturing, trafficking, distribution, and the level of involvement of organised crime
Although Hungary and Romania provided information in 
relation to the involvement of criminal groups in the 
processing, trafficking and distribution of MDMB-
CHMICA, limited information is available in relation to 
the involvement of organised crime in the manufacture 
and/or trafficking.
MDMB-CHMICA has been available on the European 
Union drug market since at least August 2014. Data from 
seizures reported to the EMCDDA and to Europol 
suggest that bulk powders of MDMB-CHMICA have been 
produced by chemical companies based in China. They 
are imported into the EU where they are either 
processed and packaged into commercial smoking 
mixtures or sold as powder. No information has been 
received by Europol indicating production of MDMB-
CHMICA within the EU.
It is important to note that in October 2015 the People’s 
Republic of China controlled MDMB-CHMICA under 
national drug control legislation.
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MDMB-CHMICA has been detected in 23 Member 
States (Austria, Belgium, Bulgaria, Croatia, Cyprus, 
Denmark, Estonia, Finland, France, Germany, Greece, 
Hungary, Latvia, Lithuania, Luxembourg, Netherlands, 
Poland, Romania, Slovenia, Spain, Sweden, Slovakia and 
the United Kingdom), Turkey and Norway.
Information reported to the EMCDDA and Europol 
indicates that over 120 kg of MDMB-CHMICA has been 
seized, as herbal material (approximately 67 kg) or 
powder form (approximately 46 kg). The largest single 
bulk seizure reported to the EMCDDA was 40 kg of 
highly pure MDMB-CHMICA in powder form by 
Luxembourg, in December of 2014. The powder was 
contained in forty 1 kg packages and was seized at 
Luxembourg airport where it was in transit from China 
(Shanghai) with Spain (Madrid). Single seizures in 
excess of 1 kg were reported by five other countries: 
Germany, Spain, Lithuania, Romania, and the 
Netherlands.
There are indications of a significant internet retail trade 
within Europe, with customs and police making regular 
seizures of small quantities of these products.
Germany reported details on an investigation that led to 
the dismantling of a processing site, where herbal 
mixtures containing MDMB-CHMICA were prepared. 
Tablets mimicking ecstasy but containing different NPS 
were also detected during this investigation. German 
authorities stated that no direct links with organised 
crime groups (OCG) have been identified.
I  Information on any assessment in the United Nations system
The World Health Organization is the specialised United 
Nations agency designated for the evaluation of the 
medical, scientific and public health aspects of 
psychoactive substances under the Single Convention 
on Narcotic Drugs of 1961 and the Convention on 
Psychotropic Substances of 1971. At the time that the 
Joint Report was prepared (6), the World Health 
Organization informed the EMCDDA that MDMB-
CHMICA was not currently under assessment nor had it 
been under assessment by the United Nations system.
I  Description of the control measures that are applicable in the Member States
Ten Member States (Croatia, Denmark, Estonia, Finland, 
Germany, Greece, Hungary, Latvia, Lithuania, and 
Luxembourg) and Turkey reported that MDMB-CHMICA 
is controlled under drug control legislation.
 § In Croatia, MDMB-CHMICA is part of the list of drugs, 
psychoactive substances and plants used for drug 
production, as well as precursors (OG 10/16). 
MDMB-CHMICA is covered with generic definition 
‘JWH-018 and its structural analogues’.
 § In Denmark, MDMB-CHMICA is controlled under drug 
control legislation.
 § In Estonia, MDMB-CHMICA has been added to drug 
control legislation since 8 June 2015.
 § In Finland, MDMB-CHMICA has been added to drug 
control legislation since 28 September 2015.
 § In Germany, by adoption of the 30th Amending 
Regulation on Narcotic Drugs (30. 
Betäubungsmittelrechts-Änderungsverordnung, 
BtMÄndV) MDMB-CHMICA is controlled under 
schedule I (narcotics not eligible for trade and medical 
prescription) of the German Narcotics Act 
(Betäubungsmittelgesetz, BtMG). The legislation has 
been published on November 11th 2015 in the 
Federal Gazette, and entered into force on 21 
November 2015 (*, see page 18).
 § In Greece, MDMB-CHMICA is classified as an isomer 
of Zipeprol (14). Zipeprol and its isomers are classified 
in the Table C of the Law 4139/2013.
 § In Hungary, MDMB-CHMICA is under drug control 
legislation from 22/07/2015 through Government 
Decree 66/2012 (IV. 2.).
 § In Latvia, MDMB-CHMICA is included in the first list of 
the Cabinet Regulation N 847 ‘Regulations regarding 
Narcotic Substances, Psychotropic Substances and 
Precursors to be Controlled in Latvia’ and the law ‘On 
the Procedures for the Coming into force and 
Application of the Criminal Law’. Control of MDMB-
CHMICA is introduced by the generic approach.
 § In Lithuania, MDMB-CHMICA has been placed under 
control, according to the Republic of Lithuania 
Minister of Health Order No V-1062 (21/09/2015) ‘On 
the amendment of the Ministry of Health of the 
Republic of Lithuania Order No. 5 of 6 January 2000.
 § In Luxembourg, MDMB-CHMICA is controlled by the 
Grand Ducale Decree of 04/05/2009.
 § In Turkey, MDMB-CHMICA is under legal control via 
the Generic Classification which was deliberated by 
(14) Systematic name: 1- methoxy-3-[4- β –methoxyphenethyl)-piperazin-
1-yl]-1-phenylpropan-2-ol
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the council of Ministers on 26/01/2015 and published 
in the official gazette on 6 February 2015 the annexed 
list subject to the provisions of the Law on Control of 
Drugs numbered 2313; according to the 19th article 
of the said Law. Generic Classification text is updated 
and adopted to the said law on 16/02/2016 by the 
council of Ministers.
Four Member States (Austria, Cyprus, Poland, and the 
United Kingdom) reported that MDMB-CHMICA is 
controlled under specific new psychoactive substances 
control legislation.
 § In Austria, MDMB-CHMICA is controlled under the 
Austrian Act on new psychoactive substances 
(Neue-Psychoaktive-Substanzen-Gesetz, NPSG).
 § In Cyprus, MDMB-CHMICA is controlled as a category 
B drug under a generic legislation since March 2016.
 § In Poland, MDMB-CHMICA is controlled according to 
the general definition of ‘substitute drug’ which has 
been included to the Act of 8 October 2010 amending 
the Act on counteracting drug addiction and the Act 
on State Sanitary Inspection (Journal of Laws ‘Dz.U.’ 
No. 213, item 1396). Article 44b of the above 
mentioned Act bans manufacturing or introducing 
substitute drugs to trade.
 § In the United Kingdom, MDMB-CHMICA is not 
controlled under the Misuse of Drugs Act 1971 but 
might be captured under the Psychoactive 
Substances Act 2016.
One Member State (Sweden) and Norway reported that 
MDMB-CHMICA is controlled under other types of 
legislation:
 § In Sweden, MDMB-CHMICA is controlled Act on the 
Prohibition of Certain Goods Dangerous to Health 
(SFS 1999:42).
 § In Norway, the import of and trade in MDMB-CHMICA 
is controlled by Medicinal Products Legislation.
Thirteen Member States (Belgium, Bulgaria, Czech 
Republic (15), France, Italy, Ireland, Malta, the 
Netherlands, Portugal, Romania, Slovakia, Slovenia and 
Spain) reported that MDMB-CHMICA is not subject to 
control measures at the national level.
(15) The Czech Republic reported that an amendment of the Government 
Regulation No. 463/2013 Coll., on the lists of addictive substances is 
currently being prepared. MDMB-CHMICA is one of the 33 substances 
proposed to place under control.
I  Options for control and the possible consequences of the control measures
Under Article 9.1 of the Council Decision, the option for 
control that is available at European Union level is for the 
Member States to submit the new psychoactive 
substance MDMB-CHMICA to control measures and 
criminal penalties, as provided for under their legislation, 
by virtue of their obligations under the Convention on 
Psychotropic Substances of 1971. There are no studies 
on the possible consequences of such control measures 
on MDMB-CHMICA. If this option of control is pursued, 
the Committee considers that the following 
consequences are possible. Some of these may apply to 
any new psychoactive substance.
 § This control option could be expected to limit the 
availability of MDMB-CHMICA and hence the further 
expansion of the current open trade in this substance.
 § A health consequence that might result from this 
control option is the benefit brought about by the 
presumed reduction in availability and use. In this 
respect it is noteworthy that the People’s Republic of 
China placed MDMB-CHMICA under national drug 
control legislation in October 2015.
 § This control option could facilitate the detection, 
seizure and monitoring of MDMB-CHMICA related to 
its unlawful manufacture, trafficking and use. In so 
doing, it could facilitate cooperation between the 
judicial authorities and law enforcement agencies 
across the European Union.
 § This control option would imply additional costs for 
the criminal justice system, including forensic 
services, law enforcement, and the courts.
 § This control option could lead to replacement with 
other (established or new) psychoactive substances, 
which may in themselves have public health 
consequences and social risks.
 § This control option could create an illicit market in 
MDMB-CHMICA with the increased risk of associated 
criminal activity, including the involvement of 
organised crime.
 § This control option could impact on both the quality/
purity and price of any MDMB-CHMICA still available 
on the illicit market. The extent to which this will 
impact on public health, criminality, or levels of use, is 
difficult to predict.
 § It is difficult to predict the impact of this control option 
on current or future research by the pharmaceutical 
or chemical industries.
 § In order to examine the consequences of control, the 
Committee wishes to note that it will be important to 
monitor for the presence of MDMB-CHMICA on the 
market post-control, should this control option be 
pursued.
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 § Aside from the option for control under those 
stipulated in Article 9.1 of the Council Decision, other 
options for control may be available to Member 
States. These may include restricting the importation 
and supply of the substance as some Member States 
have already done.
I Conclusions
The new psychoactive substance methyl 
2-[[1-(cyclohexylmethyl)-1H-indole-3-carbonyl]amino]-
3,3-dimethylbutanoate (MDMB-CHMICA) is a novel 
indole-3-carboxamide derivative. It is classed as 
a synthetic cannabinoid receptor agonist. Information on 
the pharmacology of MDMB-CHMICA is limited to in vitro 
data, which suggest that MDMB-CHMICA is a potent and 
full agonist at the CB
1
 receptor. It also acts as an agonist 
at the CB
2
 receptor.
The high potency of MDMB-CHMICA and the highly 
variable amounts of the substance in ‘legal high’ 
products constitute a high risk of acute toxicity.
MDMB-CHMICA has been available on the drug market 
in the European Union since at least August 2014 and 
has been detected in 23 Member States, Turkey and 
Norway. It is sold either as powder or commercially 
branded ‘legal high’ products by chemical companies 
and by online retail shops.
MDMB-CHMICA is typically sold as a ‘legal’ replacement 
for cannabis.
MDMB-CHMICA is typically administered by smoking 
a herbal mixture that is either from a ready-to-use 
commercial ‘legal high’ product, or, less commonly, that 
is self-prepared. Similar to herbal cannabis, the mixture 
is usually prepared for smoking as a hand-rolled 
cigarette (‘joint’) but it may also be smoked in a pipe or 
‘bong’. It can be inhaled using an e-cigarette or other 
vaporisation device.
The available data suggests that MDMB-CHMICA is used 
by cannabis users; ‘psychonauts’; and by those who are 
regularly subjected to drug testing procedures (including 
those in prison). However, no further information on the 
size and demand and the characteristics of these groups 
of people is available.
Twenty-five acute intoxications have been reported 
where MDMB-CHMICA was detected in biological 
samples taken from the patients by 4 Member States. 
Clinical features were generally consistent with 
cannabis-like toxicity but included life threatening 
conditions.
Twenty-eight deaths have been reported where MDMB-
CHMICA was detected post-mortem. In 12 (43%) of 
these cases MDMB-CHMICA was reported as either the 
cause of death or that it likely contributed to the death; in 
3 of these cases MDMB-CHMICA was the only 
substance detected.
Multiple reports have indicated a possibility for violence 
and aggression. In particular, concern was expressed 
with regard this in certain circumstances e.g. prisons 
and psychiatric institutions. In addition, the detection of 
MDMB-CHMICA in cases of suspected driving under the 
influence indicated a potential for a wider risk to public 
safety.
There is limited information to suggest the potential 
involvement of organised crime in the manufacture, 
distribution (trafficking) and supply within the European 
Union. There is limited information on the chemical 
precursors and the synthetic routes used to 
manufacture the MDMB-CHMICA detected within the 
European Union. The largest single seizure of MDMB-
CHMICA was in Luxembourg in December 2014, when 
40 kg of powder seized en-route from China to Madrid.
MDMB-CHMICA has no recognized human or veterinary 
medical use in the European Union nor, it appears, 
elsewhere. There are no indications that MDMB-CHMICA 
may be used for any other purpose aside from as an 
analytical reference standard and in scientific research.
MDMB-CHMICA is not listed for control in the Single 
Convention on Narcotic Drugs of 1961 nor in the 
Convention on Psychotropic Substances of 1971. 
MDMB-CHMICA is not currently under assessment by 
the United Nations system.
Ten Member States and Turkey control MDMB-CHMICA 
under drug control legislation and five Member States 
and Norway control MDMB-CHMICA under other 
legislation.
As for any new psychoactive substance, many of the 
questions related to MDMB-CHMICA that are posed by 
the lack of data on the risks to individual health, risks to 
public health, and social risks, could be answered 
through further research. Areas where additional 
information would be important include studies on: 
rationale for use, prevalence and patterns of use 
(including targeted studies that examine user groups 
and risk behaviours); the market; chemical profiling; 
complete pharmacological profiling; metabolic 
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pathways; behavioural effects; acute and chronic 
toxicity; the potential interaction between MDMB-
CHMICA and other substances; the dependence and 
abuse potential; and the public health risks associated 
with its use.
The Committee notes that a decision to control MDMB-
CHMICA has the potential to bring with it both intended 
and unintended consequences. Potential intended 
consequences include reduced levels of availability and 
ultimately use. This may reduce the health and social 
risks and consequences arising from the use of MDMB-
CHMICA. It is important to recognise that a potential 
unintended consequence of control may be the 
manufacture and availability of other substances. 
Indeed, chemically analogous substances that may 
replace MDMB-CHMICA are already being sold on the 
drug market. The implementation of control measures 
may also lead to the criminalisation of those who 
continue to use this substance with the possible 
attendant risks of socio-economic stigmatisation and 
marginalisation. Should control measures be adopted, 
they should be accompanied by the gathering and 
dissemination of accurate information on MDMB-
CHMICA to users, practitioners, policy makers, and 
decision makers.  
(*) The information originally reported on the control measures 
applicable in Germany is indicated in section ‘Description of 
the control measures that are applicable in the Member States’. 
However, it was later clarified that MDMB-CHMICA is listed 
under schedule II (narcotics eligible for trade but not for 
medical prescription) of the German Narcotics Act 
(Betäubungsmittelgesetz, BtMG).
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ANNEX 1
Technical report on methyl 
2-[[1-(cyclohexylmethyl)-1H- 
indole-3-carbonyl]amino]-3,3-
dimethylbutanoate (MDMB-
CHMICA)
Dr Bjoern Moosmann and Prof. Dr Volker Auwärter
Data sources
The information in this technical report is derived from:
data reported by the Member States to the EMCDDA 
and Europol in accordance with Council Decision 
2005/387/JHA on the information exchange, risk-
assessment and control of new psychoactive 
substances (1); and,
data collected through systematic searches of open 
source information, including the scientific and medical 
literature, patents, official reports, grey literature, Internet 
drug discussion forums and related websites, and online 
vendors selling MDMB-CHMICA.
Search strategy
Medline and Google Scholar were searched for ‘MDMB-
CHMICA’, ‘MMB-CHMINACA’, and the IUPAC names of 
this compound stated in this document.
Exact chemical structure-based searches were done in 
SciFinder (American Chemical Society, Chemical 
Abstract Service) and Reaxys (Elsevier).
Google, Internet drug user forums (such as Erowid, 
Bluelight, Reddit and Eve and Rave) were searched for 
the terms: ‘MDMB-CHMICA’, ‘MMB-CHMINACA’, alone or 
in combination with ‘buy’, ‘shop’, ‘research chemical’, 
‘synthetic cannabinoid’, ‘dosing’, ‘intoxication’, ‘kaufen’, 
‘räuchermischung’, ‘powder’, ‘synthesis’.
(1) OJ L 127, 20.5.2005, p. 32. 
Additionally, the scientific networks of the authors were 
contacted to obtain information.
Note
It is important to note that when interpreting the data on 
self-reported user experiences that is provided in this 
report, it is not possible to confirm the specific 
substance(s) used; similarly it is also not possible to 
confirm the strength, purity, dose/amount, etc., used. In 
addition, the information provided on user websites and 
from specific user groups may not necessarily be 
representative of other users of MDMB-CHMICA and 
should be regarded as illustrative only.
I  Section A. Physical, chemical, pharmaceutical and pharmacological information
|  A1. Physical, chemical, and pharmaceutical information
A1.1. Physical and chemical description
Chemical description and names
Methyl 2-[[1-(cyclohexylmethyl)-1H-indole-3-carbonyl]
amino]-3,3-dimethylbutanoate (MDMB-CHMICA) is an 
N-cyclohexylmethyl indole-3-carboxamide (Figure 1). 
This substance is classified as a synthetic cannabinoid 
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receptor agonist, a chemically diverse group of 
substances also referred to as synthetic 
cannabinoids (2).
Synthetic cannabinoid receptor agonists are a large 
family of chemically unrelated structures functionally 
similar to Δ9-tetrahydrocannabinol (THC), the 
psychoactive principle of cannabis. Like THC, they bind 
to the same cannabinoid receptors in the brain and other 
organs. They were developed over the past 40 years as 
potential pharmaceutical agents, often intended for pain 
management.
Cannabinoid receptor agonists controlled under the 
1971 United Nations Convention on Psychotropic 
Substances (Schedule II) are: the major active principle 
of cannabis, delta-9-tetrahydrocannabinol (Δ9-THC) and 
its stereochemical variants (3) and two aminoalkylindole 
synthetic cannabinoid receptor agonists: JWH-018 (4) 
(Commission on Narcotic Drugs, 2015a) and AM-2201 
(5) (Commission on Narcotic Drugs, 2015b). JWH-018 
was the first synthetic cannabinoid reported to the EU 
Early Warning System (EU EWS) (6) (EMCDDA, 2009) 
and AM-2201 is the 5-fluoropentyl analogue of JWH-018 
(2) For the purposes of monitoring within the framework of the EU Early 
Warning System, the term ‘synthetic cannabinoids’ is used to include: 
the large number of synthetic cannabinoid (CB1 and CB2) receptor 
agonists that have been detected on the European drug market; 
a much smaller number of allosteric modulators (such as Org 27569) 
that change the structure of the cannabinoid receptors leading to 
altered activity when a ligand binds to the receptors; and substances 
that act as inhibitors of fatty-acid amide hydrolase (FAAH), which is 
the enzyme responsible for breaking down the endocannabinoid 
anandamide (such as URB597). 
(3) Also controlled are the following isomers: Δ6a(10a), Δ6a(7), Δ7, Δ8, Δ10, 
Δ9(11) and their stereochemical variants.
(4) (Naphthalen-1-yl)(1-pentyl-1H-indol-3-yl)methanone
(5) 1-(5-Fluoropentyl)-1H-indol-3-yl]-(naphthalen-1-yl)methanone
(6) Forensic investigators in Germany and Austria detected the synthetic 
cannabinoid JWH-018 in a product sold under the brand name ‘Spice’.
(Figure 2). The controls on JWH-018 and AM-2201 
entered into force in November 2015.
The abbreviation used for MDMB-CHMICA is derived 
from its chemical name (EMCDDA, 2016): ‘MDMB’ 
stands for methyldimethylbutanoate; ‘CHM’ stands for 
cyclohexylmethyl; ‘I’ stands for indole; and ‘CA’ stands 
for carboxamide. MDMB-CHMICA was first advertised as 
‘MMB-CHMINACA’, which would falsely imply an 
indazole core structure. Online shops continue to offer 
this substance under the name ‘MMB-CHMINACA’.
Examples of structurally related synthetic cannabinoid 
receptor agonists currently monitored by the EMCDDA, 
which also contain a cyclohexylmethyl and 
a carboxamide moiety are given in Figure 3, where 
abbreviations have been used.
FIGURE 1
The molecular structure, molecular formula and 
molecular mass of MDMB-CHMICA.
N
O
N
O
O
MDMB-CHMICA
Molecular formula: C
23
H
32
N
2
O
3
Molecular weight: 384.5118 g/mol
Monoisotopic mass: 384.2413
FIGURE 2
The molecular structure, molecular formula and 
molecular mass of JWH-018 and AM-2201.
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ADB-CHMICA and AMB-CHMICA have an indole core in 
common with MDMB-CHMICA. AB-CHMINACA, ADB-
CHMINACA and AMB-CHMINACA have an indazole core 
instead; AB-CHMFUPPYCA has a pyrazole core; and 
MDMB-CHMCZCA has a carbazole core.
Systematic names for MDMB-CHMICA compatible with 
the IUPAC (International Union of Pure and Applied 
Chemistry) nomenclature:
 § methyl 2-({[1-(cyclohexylmethyl)-1H-indol-3-yl]
carbonyl}amino)-3,3-dimethylbutanoate or
 § methyl 2-{[1-(cyclohexylmethyl)-1H-indol-3-yl]
formamido}-3,3-dimethylbutanoate or
 § methyl N-{[1-(cyclohexylmethyl)-1H-indol-3-yl]
carbonyl}-3-methylvalinate
N-(1-methoxy-3,3-dimethyl-1-oxobutan-2-yl)-1-
(cyclohexylmethyl)-1H-indole-3-carboxamide (name 
used in the Chinese regulation published in 2015 (7))
(7) China Food and Drug Administration (CFDA), 2015. Available at: 
http://www.sfda.gov.cn/WS01/CL0056/130753.html. 
FIGURE 3
Chemical structures of ADB-CHMICA, AMB-CHMICA, AB-CHMINACA, ADB-CHMINACA, AMB-CHMINACA, 
AB-CHMFUPPYCA and MDMB-CHMCZCA.
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IUPAC International Chemical Identifier (InChI)
InChI=1S/C23H32N2O3/c1-23(2,3)20(22(27)28-4)24-
21(26)18-15-25(14-16-10-6-5-7-11-16)19-13-9-8-12-
17(18)19/h8-9,12-13,15-16,20H,5-7,10-11,14H2,1-
4H3,(H,24,26)
Standard InChI Key: SRJKCVHWIDFUBO-
UHFFFAOYSA-N
Simplified Molecular-Input Line-Entry System (SMILES)
SMILES: C1(CCCCC1)CN1C=C(C2=CC=CC=C12)C(=O)
NC(C(=O)OC)C(C)(C)C
Chemical Abstract Service Registry Number (CAS RN):
CAS RN: 1863065-84-2
‘CAS RN’ referenced on the Internet and used in the 
Chinese regulation (7)(8): 1715016-78-6.
Other names:
MMB-CHMINACA
Street names:
Some of the street names used commonly for products 
containing synthetic cannabinoid receptor agonists are: 
‘Spice’, ‘K2’, ‘legal weed’, ‘synthetic cannabis’, ‘herbal 
incense’.
A list of street names reported for products containing 
MDMB-CHMICA purchased online in as part of the 
EU-funded projects ‘SPICE II Plus’ (9) and ‘SPICE 
Profiling’ (10) are provided in Appendix 1. It should be 
noted that there can be considerable variability both 
within and between different batches of products sold 
under specific brand names, in terms of both the 
substances and the amount present.
Other street names reported to the EMCDDA are: 
Godfather, CUSHCottonCandy, KUSHSecondGereration, 
KUSHherbal incense, Ninja, Sirius, SKIHIGH, CRITICAL 
haze.
(8) A search of this CAS number in pubchem.ncbi.nlm.nih.gov returns the 
indazole analogue of MDMB-CHMICA, incorrectly labelled as 
‘MDMB-CHMICA’. See: https://pubchem.ncbi.nlm.nih.gov/
compound/119058045 
(9) JUST/2011/DPIP/AG/3597 
(10) JUST/2013/ISEC/DRUGS/AG/6421 
Stereochemistry
MDMB-CHMICA contains a stereogenic centre thus 
allowing for the existence of a pair of enantiomers, 
(S)-MDMB-CHMICA and (R)-MDMB-CHMICA. There is 
no representative information on the isomeric 
composition of the samples of MDMB-CHMICA detected 
within the European Union, which in part may reflect the 
fact that stereochemical analysis is not routinely 
undertaken in forensic laboratories.
In an article by Andernach et al., the isomeric 
composition and the optical purity of five samples of 
herbal products containing MDMB-CHMICA have been 
analysed (Andernach et al., 2016). In addition, a sample 
from a 40 kg seizure made by customs in Luxembourg in 
December 2014 (Section C) was analysed in the same 
study. All the samples were found to contain the (S) 
isomer and to be of very high optical purity.
Some reference material suppliers such as Cayman 
Chemical (Cayman Chemical Company, 2015) and 
Toronto Research Chemicals (Toronto Research 
Chemicals, 2016) list the (S)-enantiomer for sale. Other 
suppliers (Cerilliant, 2016; LGC Standards, 2016) do not 
indicate which is the stereoisomeric form sold as 
a reference material.
Identification and analytical profile
MDMB-CHMICA was first identified in a seizure made in 
Hungary in August 2014. There is no information 
published in the scientific or patent literature prior to this 
first detection.
The analytical profile of MDMB-CHMICA has been 
described in a publication using NMR, LC-HRMS, IR and 
UV-VIS detection (Langer et al., 2016). The UV maxima of 
MDMB-CHMICA are reported at 216 and 290 nm in 
methanol and IR data as follows: wavenumber (cm-1): 
3325 (w), 3105 (w), 2926 (m), 2852 (w), 1738 (m), 1616 
(s), 1536 (s), 1511 (s), 1464 (m), 1395 (m), 1217 (m), 
1196 (m), 1157 (s), 1129 (m), 1014 (m), 776 (m), 742 (s), 
618 (m), 549 (m) (Langer et al., 2016).
A recent study described the fragmentation patterns of 
MDMB-CHMICA (Akamatsu and Yoshida, 2016).
A full analytical profile is also available from the 
Slovenian National Forensic Laboratory, which analyses 
test-purchased products within the EU-funded project 
Response to challenges in forensic drug analysis (11).
(11) Analytical profile available at: http://www.policija.si/apps/nfl_
response_web/0_Analytical_Reports_final/MDMB-CHMICA-ID-
1190-15-report_final.pdf
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Quantification of MDMB-CHMICA in herbal smoking 
blends has been analysed using NMR (Dunne et al., 
2016). The study analysed 63 herbal smoking blends and 
concentration of substances within the blends varied 
from 1.5 % (w/w) for MDMB-CHMICA to over 5 % (w/w) 
for another synthetic cannabinoid 5F-AKB-48. 
Quantification of MDMB-CHMICA in products can be 
carried out according to the general procedure 
described by UNODC, e.g. by HPLC-DAD analysis 
(United Nations Office on Drugs and Crime, 2013).
Detection of MDMB-CHMICA in biological samples
In the analysis of serum samples, the main analytical 
target is the parent compound. In an unpublished study 
by the authors (Moosmann and Auwärter, 2016, 
unpublished), the concentration of MDMB-CHMICA was 
quantified in 225 serum samples positive for the 
substance. The concentrations were in the range of ng/
ml (mean: 2.9 ng/ml, median: 0.5 ng/ml, range <0.1 – 91 
ng/ml, n=225). Therefore, due to its high sensitivity, 
LC-MS/MS is the most appropriate technique for 
quantifying the substance. Three methods for the 
detection of MDMB-CHMICA in serum samples have 
been published in the literature so far, all of them using 
LC-MS/MS (Adamowicz, 2016; Angerer et al., 2016; 
Westin et al., 2016).
In the analysis of urine, the main metabolites need to be 
identified prior to setting up a method, as MDMB-
CHMICA is not excreted unchanged in urine to a relevant 
extent. Based on the analysis and evaluation of ten urine 
samples from different individuals (Moosmann and 
Auwärter, 2016, unpublished), three mono-hydroxylated 
(hydroxylation at the cyclohexyl moiety) and the 
carboxylic acid ester hydrolysis product appear to be the 
most suitable targets for the detection of MDMB-
CHMICA exposure.
When interpreting analytical findings it should be noted 
that some of the substances in which MDMB-CHMICA is 
metabolised into may be also formed after exposure to 
other synthetic cannabinoid receptor agonists.
For example, the metabolites that undergo ester 
hydrolysis are also formed after exposure to ADB-
CHMICA. Additionally, one minor metabolite of MDMB-
CHMICA (hydrolysis of the amide) is identical with one of 
the major metabolites of the synthetic cannabinoid 
BB-22 (QUCHIC) (12)(13). Since no commercial reference 
material is available for the metabolites, 
misidentification could occur due to the fact that MDMB-
(12) Quinolin-8-yl 1-(cyclohexylmethyl)-1H-indole-3-carboxylate 
(13) More information on the pharmacodynamics and pharmacokinetics of 
this substance is available in Section A2. 
CHMICA and BB-22 have identical nominal masses for 
certain metabolites and show very similar fragmentation 
patterns (Franz et al., 2016).
Another aspect which has to be considered is the 
thermolytic formation of two MDMB-CHMICA 
metabolites during smoking which could bias the 
detected metabolic profile.
Physical description
In its pure form MDMB-CHMICA is an odourless, white 
and crystalline solid. It is soluble up to approximately 20 
mg/ml in dimethylformamide and 5 mg/ml in dimethyl 
sulfoxide (Cayman Chemical Company, 2015). The 
substance is expected to be poorly soluble in water.
The melting point is stated to be 133-134°C (Toronto 
Research Chemicals, 2016).
The boiling point is not available in the literature; 
however, it can be estimated to be below 350°C 
according to its retention time in GC-MS analysis.
Chemical stability and typical reactions
Storage in solution or under non-ideal conditions (e.g. 
high humidity or elevated temperatures) can lead to 
hydrolysis of the carboxylic ester. Ester hydrolysis was 
shown to occur during smoking by analysis of smoke 
condensates (Moosmann and Auwärter, 2016, 
unpublished). Most of the known free carboxylic acids 
formed by hydrolysis of similar compounds are not active 
at the CB
1
-receptor (Buchler et al., 2009; Buchler et al., 
2011). Therefore, the hydrolysis product of MDMB-
CHMICA might not be active as a cannabinoid.
In the presence of ethanol, transesterification can lead 
to the formation of the ethyl ester derivative, which may 
bind to the CB
1
-receptor. Reaction with other alcohols 
could lead to corresponding ester compounds.
The amide bond may be cleaved chemically or 
enzymatically.
Methods and chemical precursors used for the 
manufacture of MDMB-CHMICA
No information was reported to the EMCDDA about the 
chemical precursors or manufacturing methods used to 
make the MDMB-CHMICA which has been detected on 
the drug market in Europe.
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Detailed information available with regards to route-
specific by-products produced during the synthesis of 
MDMB-CHMICA is currently not available.
Synthesis
The synthesis of MDMB-CHMICA may be carried out 
similarly to the synthesis of its indazole analogue, 
MDMB-CHMINACA, which has been described in 
a patent application (Buchler et al., 2009; Buchler et al., 
2011) or in analogy to similar compounds, as described 
by Banister (Banister et al., 2015) and Adam (Adam et 
al., 2010). Possible synthesis routes are available in 
Appendix 2 of the Technical report.
According to the synthetic routes described in Appendix 
2, potential precursors of MDMB-CHMICA are L-tert-
leucine methyl ester (for synthesis of the (S) 
enantiomer), indole-3-carboxylic acid, indole-3-
carboxylic acid methyl ester, indole and 
cyclohexylmethyl bromide.
Typical impurities encountered in seized and 
collected samples
There are no quantitative data available on the impurities 
detected in seized and collected samples reported to 
the EMCDDA.
Impurities identified in powders containing MDMB-
CHMICA analysed by the Federal Criminal Police Office 
of Germany (in German, Bundeskriminalamt) are: 
‘MDMB-CHMICA-2-Cl-analogue’ (14) ‘tert-leucine-
MDMB-CHMICA’ (15) and CHMICA-N,N-dimethyl-
analogue (16) (Moosmann & Auwärter, 2016).
Commercially available products which could be used 
for synthesis of MDMB-CHMICA may contain other 
potentially toxic substances, including heavy metals and 
organic solvents. Use of such products as reagents may 
result in serious toxic effects if the resultant impure 
product is consumed. The herbal material which is used 
as a basis for the smoking mixtures may contain 
toxicologically relevant substances such as heavy 
metals and pesticides potentially present in the plant 
material.
(14) IUPAC name: methyl N-({1-[(2-chlorocyclohexyl)methyl]-1H-indol-3-yl}
carbonyl)-3-methylvalinate)
(15) IUPAC name: methyl N-{[1-(cyclohexylmethyl)-1H-indol-3-yl]carbonyl}-
3-methylvalyl-3-methylvalinate
(16) IUPAC name: 1-(cyclohexylmethyl)-N,N-dimethyl-1H-indole-3-
carboxamide
A1.2. Physical/pharmaceutical form
Data from seizures and collected samples reported to 
the EMCDDA have noted that MDMB-CHMICA has 
typically been detected in the form of herbal material 
(Section C). Over 90% of the total number of seizures 
reported by countries where MDMB-CHMICA has been 
detected have been of herbal material (EMCDDA and 
Europol, 2016). This includes the seizure of a number of 
commercial branded ‘legal high’ products. MDMB-
CHMICA has also been detected in powder form.
MDMB-CHMICA is sold by Internet retailers either as 
commercial branded ‘legal high’ products in the form of 
herbal material or as a powder, typically advertised as 
‘research chemicals’.
For the production of ‘herbal mixtures’ the synthetic 
cannabinoid(s) is mixed with or sprayed/soaked onto the 
plant material – mostly damiana (Turnera diffusa) or 
marshmallow (Althaea officinalis) – using solvents such 
as acetone or methanol to dissolve the powders. Once 
mixed, the mixtures are then dried and solvent is 
evaporated. Typically this is done on a large scale, using 
equipment like cement mixers to mix the ingredients 
together.
A case reported to Europol by German police indicates 
that MDMB-CHMICA has been impregnated on writing 
paper along with other cannabinoids to writing paper 
and was used by prisoners. The prisoners cut the writing 
paper into pieces and smoked them mixed with tobacco 
(one unit of administration estimated as a 2x2 cm piece 
of paper).
Some countries have reported finding other synthetic 
cannabinoid receptor agonists in products that look like 
cannabis resin, either in branded ‘legal high’ products or 
simply passed off as cannabis resin on the illicit market. 
In a small number of cases, the presence of synthetic 
cannabinoid receptor agonists has been detected in 
what appear to be ecstasy tablets or capsules. Another 
recent development has been the discovery of synthetic 
cannabinoid receptor agonists in the liquid-filled 
cartridges for use in electronic cigarettes; this most likely 
reflects the recent popularity of ‘vaping’ among young 
people.
The detection of MDMB-CHMICA in liquid form, tablets 
or capsules has not been reported to the EMCDDA.
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A1.3. Route of administration and dosage
Route of administration
The most common route of administration for synthetic 
cannabinoid receptor agonists, including MDMB-
CHMICA, is smoking either ready-to-use commercial 
branded ‘legal high’ products or self-prepared herbal 
mixtures as a joint or utilizing a vaporizer, ‘bong’ or pipe. 
Oral administration of other synthetic cannabinoid 
receptor agonists has also been described. In the case 
of oral administration a strong metabolism can be 
expected.
See Section D.1.2.2 for more information on route of 
administration reported for individuals with had serious 
adverse events associated with the use of MDMB-
CHMICA.
Some synthetic cannabinoid receptor agonists (e.g. 
5F-cumyl-PINACA, AKB-48-5F) are also offered in the 
form of eliquids for administration in an electronic 
cigarette, but no such products containing MDMB-
CHMICA have been reported so far (EMCDDA and 
Europol, 2016). However, reports on the Internet state 
that some users prepare MDMB-CHMICA containing 
e-liquids at home by dissolving in propylene glycol.
Dosage
It is important to note that when interpreting the data on 
self-reported user experiences that it is not possible to 
confirm the specific substance(s) used; similarly it is also 
not possible to confirm the strength, purity, dose/
amount, etc., used. In addition, the information provided 
on user websites and from specific user groups may not 
necessarily be representative of other users of MDMB-
CHMICA and should be regarded as illustrative only.
Self-reported user experiences posted in Internet drug 
discussion forums (Bluelight, 2016; Erowid, 2016; 
Reddit, 2016), have reported doses of MDMB-CHMICA 
that range from 120 µg to 15 mg (Appendix 3). Doses 
above 1 mg have been generally described as ‘strong’ or 
‘very strong’. Doses above 5 mg have been reported by 
non-naïve users.
The doses by route of administration reported by users 
are given in Table 1 (source: systematic review that 
analyses 36 reports from MDMB-CHMICA users on 
internet discussion forums, Dargan et al., 2016b, 
unpublished).
TABLE 1
Routes of administration of MDMB-CHMICA, dose and duration of effects by number of reports (source: Dargan et 
al., 2016b, unpublished).
Route of 
Administration
No. of 
reports (%)
Dose Time to Onset Duration of Symptoms
N=38 n
Median 
(mins)
IQR n
Median 
(mins)
IQR n
Median 
(mins)
IQR
Smoked 24 (63.2) 9 5 5 - 8 12 1 1 - 1 12 120 60 - 172.5
E-cigarette inhalation 5 (13.2) 1 0.5 - 1 30 - 2 120 120 - 120
Oral ingestion 4 (10.5) 2 12 8 - 16 3 120 61.5 - 120 1 180 -
Rectal insertion 1 (2.6) 1 0.12 - 1 15 - 1 180 -
Not Reported 3 (7.9)
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|  A2. Pharmacology, including pharmacodynamics and pharmacokinetics
THC and other cannabinoids (endogenous or synthetic) 
mediate their actions by binding to the cannabinoid 
receptors of which there are at least two types, classed 
as CB
1
 and CB
2
 found in mammalian tissues (Pertwee, 
2004). The CB
1 
receptors are located primarily in central 
and peripheral neurons whilst CB
2 
receptors are primarily 
expressed outside of the central nervous system and 
play a role with the immune system. Although there is 
some conflicting evidence in the literature, it is believed 
that activation of CB
1
 receptors by endogenous 
cannabinoids is said to play a role in neuronal signalling 
involved dopamine, glutamate and GABA (Pertwee, 
2004; Seely et al., 2012).
Activation of CB
1
 receptors by THC – the major 
psychoactive principle in cannabis – results in sedative, 
analgesic, psychedelic and anxiolytic effects (Ashton, 
2001). It is also more commonly associated with 
a euphoric effect of being “high” with colours appearing 
brighter, music more appealing and changes in emotion 
(Ashton, 2001). Cannabis can also induce a tachycardia 
and a reddening of the conjunctivae (Paton et Pertwee, 
1973). Reaction times and motor skills can also be 
reduced.
THC has partial agonist activity at the CB
1
 receptor in 
certain neuronal areas (Seely et al., 2012; Wiley et al., 
2015).
Pharmacodynamics
Published data on the pharmacodynamics of MDMB-
CHMICA are limited to in vitro studies.
Indole and indazole synthetic cannabinoid receptor 
agonists (SCs) were synthesized and assessed for 
cannabimimetic activity in vitro and in vivo by Banister et 
al. (Banister et al., 2016), using a fluorometric assay of 
membrane potential. The (S) enantiomer of MDMB-
CHMICA was synthetised and studied in this paper. All 
the compounds studied, including (S)-MDMB-CHMICA, 
activated CB
1 
and CB
2 
receptors, displaying greater 
potency (10 nM for (S)-MDMB-CHMICA) than either 
Δ9-THC (171 nM) or CP 55,940 (42 nM) for CB
1 
receptor-
mediated activation of G protein-coupled inwardly-
rectifying potassium channels (GIRK). Most of the 
studied compounds, including (S)-MDMB-CHMICA, had 
a similar maximal effect to CP 55,940 at CB
1 
and CB
2 
receptors, suggesting that these SCs are also high 
efficacy agonists. (S)-MDMB-CHMICA showed 
a preference for CB
1 
receptors over CB
2
 receptors (7.1).
Although specific data are not presented, a study 
evaluating the binding affinity of 54 newly-emerged 
synthetic cannabinoid receptor agonists at the 
cannabinoid CB
1
 and CB
2
 receptors revealed that most 
of the substances had almost the same or higher CB
1
 
and CB
2
 receptor binding affinities as compared to 
JWH-018 and that MDMB-CHMICA ‘was one of the 
substances with the highest binding affinities at the CB
1 
receptor’ in the study (Kikura-Hanajiri, 2015). At present, 
no further details are available, since this publication is 
available in abstract form only.
The available data suggests that MDMB-CHMICA is 
a potent efficaceous agonist at the CB
1
 receptor of the 
endocannabinoid system. Using a cAMP assay, MDMB-
CHMICA showed an EC
50
 approximately 8 times lower 
than the EC
50
 of JWH-018, and a twofold lower EC
50
 than 
AB-CHMINACA (17)(18) (Table 3) (Moosmann and 
Auwärter, 2016, unpublished).
(17) The EC50 is the concentration of a drug which produces 50% of the 
maximum possible response in a dose response curve. The lower the 
EC50 value is indicative of a higher potency.
(18) Systematic name: N-[(1S)-1-(aminocarbonyl)-2-methylpropyl]-1-
(cyclohexylmethyl)-1H-indazole-3-carboxamide.
TABLE 2
Functional activity of Δ9-THC, CP 55,490 and (S)-MDMB-CHMICA at CB
1 
and CB
2 
receptors.
Compound
hCB
1
hCB
1
hCB
2
hCB
2
CB
1
 sel
pEC
50
 ± SEM
(EC
50
, nM)
Max ± SEM
(% CP 55,940
pEC
50
 ± SEM
(EC
50
, nM)
Max ± SEM
(% CP 55,940
Expressed as the 
ratio of CB
1
 EC
50
 to 
CB
2
 EC
50
Δ9-THC 6.77 ± 0.05 (171) 50 ± 11 20 ± 3 at 10 µM
CP 55,490 7.47 ± 0.05 (42) - 7.17 ± 0.07 (68) - 1.6
(S)-MDMB-CHMICA 8.00 ± 0.05 (10) 112 ± 3 7.16 ± 0.05 (71) 103 ± 3 7.1
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TABLE 3
Half maximal effective concentration (EC50) and 
efficacy (Emax) as compared to the full agonist CP 
55,940 of MDMB-CHMICA and other synthetic 
cannabinoids as assessed using a cAMP assay (CB1 
receptor, DiscoverX) (Moosmann and Auwärter, 2016, 
unpublished).
Compound EC
50
 [nM] E
max
MDMB-CHMICA 0.14 94%
AB-CHMINACA 0.27 94%
AB-FUBINACA 0.89 97%
JWH-018 1.13 97%
Structure activity relationship (SAR) studies comparing 
different synthetic cannabinoid receptor agonists have 
been published (see information below). MDMB-
CHMICA appears to have some of the structural features 
(i.e. an indole core, a tert-butyl moiety, and 
a carboxamide methyl ester) that have been associated 
with low CB
1
 values (higher activity at the CB
1 
receptor).
Structure activity relationships show that the 
substitution of the indole core with an indazole core is 
expected to lead to a significant reduction of the activity 
at the CB
1
 receptor. This is observed in the case of APICA 
(19) (indole core) and APINACA (20) (indazole core) (IC
50
: 
175 nM vs. 824 nM) (Uchiyama et al., 2012) and in the 
case of AM-2201 (indole core) and THJ-2201 (indazole 
core) (EC
50
: 0.45 nM vs. 1.68 nM) (Moosmann and 
Auwärter, 2016, unpublished).
The introduction of a tert-butyl moiety (e.g. ADB-
CHMINACA(21)) is expected to lead to an increase in 
affinity towards the CB
1
 receptor as compared to 
compounds that carry an isopropyl moiety (e.g. AB-
CHMINACA) (ADB-CHMINACA K
i
: 0.289 nM; EC
50
:IC
50
 
0.62 nM vs. AB-CHMINACA K
i
: 0.519 nM; EC
50
:IC
50
 
2.55 nM) (Moosmann and Auwärter, 2016, unpublished).
Furthermore, a terminal carboxamide (e.g. ADB-
CHMINACA) is related to a decrease in activity as 
compared with its methyl ester analogue (e.g. MDMB-
CHMINACA) (ADB-CHMINACA K
i
: 0.289 nM; EC
50
:IC
50
 
0.62 nM vs. MDMB-CHMINACA K
i
: 0.094 nM; EC
50
:IC
50
 
0.330 nM) (Buchler et al., 2009; Buchler et al., 2011; 
Banister et al., 2015).
(19) Systematic name: N-(1-adamantyl)-1-pentyl-1H-indole-3-
carboxamide.
(20) Systematic name: N-(1-adamantyl)-1-pentyl-1H-indazole-3-
carboxamide.
(21) Systematic name: N-[1-(aminocarbonyl)-2,2-dimethylpropyl]-1-
(cyclohexylmethyl)-1H-indazole-3-carboxamide.
There are no data available on the effect of MDMB-
CHMICA on other pharmacological targets.
The pharmacological properties of the metabolites of 
MDMB-CHMICA are not known. It has been previously 
shown that the mono-hydroxylated metabolites of 
cannabinoids such as JWH-018, JWH-073 and THC 
have activity at the CB
1
 receptor. It is therefore possible 
that the mono-hydroxylated metabolites of MDMB-
CHMICA may contribute to the pharmacological profile 
of the compound. It should be noted, however, that it is 
unclear if these metabolites will be able to cross the 
blood-brain-barrier and reach effective concentrations 
levels in the central nervous system.
Pharmacokinetics
There is limited information in the literature concerning 
the pharmacokinetics of MDMB-CHMICA.
MDMB-CHMICA is expected to undergo extensive 
metabolism in the human body. Similar to other 
synthetic cannabinoid receptor agonists which have 
been previously studied (Erratico et al., 2015, Hegstad et 
al., 2015), it is not excreted unchanged in urine to 
a relevant extent. A recent study by Franz and co-
workers (Franz et al., 2016) found that MDMB-CHMICA 
was not detectable in any of the human urine samples 
analysed unchanged (n = 10) which were positive for 
MDMB-CHMICA in serum, in addition, degradation 
during sample preparation could be excluded.
A study by Moosmann and co-workers (Moosmann and 
Auwärter, 2016, unpublished) has identified a total of 31 
metabolites of MDMB-CHMICA in vivo. The four most 
abundant metabolites detected were either products of 
the mono-hydroxylation of the cyclohexyl moiety or 
products of the hydrolysis of the carboxylic ester 
function. Given the metabolites found, it is thought that 
the main metabolic reactions comprise mono-
hydroxylations and hydrolysis of the carboxylic ester 
function (similarly to what occurs for AB-CHMINACA).
A study by Dobos and co-workers (Dobos et al., 2015) 
has identified the carboxylate derivative formed by ester 
hydrolysis as the main metabolite of MDMB-CHMICA in 
human urine.
Metabolites specific to MDMB-CHMICA have been 
identified. A study by Franz and co-workers (Franz et al., 
2015) suggests that the cyclohexyl-methyl hydroxylated 
product of MDMB-CHMICA is a potential target for the 
identification of the compound in human urine samples.
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In addition, a study by Grigoryev and co-workers 
(Grigoryev et al., 2016) suggest that metabolites with 
a hydroxyl on the cyclohexyl moiety and carboxyl group 
would be the most useful marker in urine analysis for this 
type of synthetic cannabinoid.
Interactions with other drugs or medicines
No studies were identified that have examined the 
interaction of MDMB-CHMICA with other substances, 
including medicinal products.
| A3. Psychological and behavioural effects
Information on the psychological and behavioural effects 
of MDMB-CHMICA is limited to serious adverse events 
reported to the EMCDDA, case reports published in the 
scientific literature and self-reported user experiences 
published in Internet drug discussion forums and related 
websites.
Some users report that the effects of MDMB-CHMICA 
are comparable to the effects of cannabis, with a more 
pronounced euphoria. In summary, reported 
psychological and behavioural effects after use of 
MDMB-CHMICA include: increased appetite, nausea and 
vomiting, tachycardia, inability to move, numbness of 
extremities, shivering, feeling of warmth, laughing, 
changes in mood (for example alternating crying and 
singing), disorientation, confusion, lack of concentration 
and short-term memory, vertigo, tiredness, visual and 
auditory hallucinations, agitation, severe anxiety and 
fear/panic, psychosis, dissociation, violent behaviour, 
aggression and ‘acute behavioural disturbances’. These 
effects are consistent with known psychological and 
behavioural effects of synthetic cannabinoid receptor 
agonist use (Tait et al., 2016; Kronstrand et al., 2013) 
(see Section D1.2.1 and Section D3.3).
The most common psychological effect reported by 
users was euphoria (11; 30.6%), followed by visual 
hallucinations (6; 16.7%) (source: systematic review that 
analyses 36 reports from MDMB-CHMICA users on 
internet discussion forums, Dargan et al., 2016b, 
unpublished) (see Section D1.2.1).
| A4. Legitimate uses of the product
As a result of its appearance on the drug market, 
MDMB-CHMICA and its (S) enantiomer are used in 
scientific research as well as analytical reference 
materials in clinical and forensic case work/
investigations. There is currently no other information 
that suggests MDMB-CHMICA may be used for other 
legitimate purposes.
There are no reported uses of MDMB-CHMICA as 
a component in industrial, cosmetic or agricultural 
products. In addition, a search of the REACH registered 
substances database hosted by the European 
Chemicals Agency (ECHA) using the CAS Registry 
Number returned no results.
There is no marketing authorisation (existing, ongoing or 
suspended) for MDMB-CHMICA neither in the European 
Union nor in the Member States that responded to the 
request for information from the European Medicines 
Agency which was undertaken as part of the Joint 
Report process (EMCDDA and Europol, 2015).
There is no information to suggest that MDMB-CHMICA 
is currently used in the manufacture of a medicinal 
product in the European Union. However, in the absence 
of a European Union database on the synthetic routes of 
all medicinal products it is not possible to confirm 
whether or not MDMB-CHMICA is currently used in the 
manufacture of a medicinal product.
I  Section B. Dependence and abuse potential
| B1. Animal data
No studies were identified that have investigated the 
dependence and/or abuse potential of MDMB-CHMICA 
in animals.
The dependence potential of two other synthetic 
cannabinoid receptor agonists have been studied in 
animals by Ginsburg and co-workers (Ginsburg et al., 
2012) and can provide some insight into the 
dependence and abuse potential of MDMB-CHMICA. 
According to the study, ‘the relatively short duration of 
action of JWH-018 and JWH-073 [relative to Δ9-THC] 
may lead to a more frequent use, which could strengthen 
habitual use by increasing the frequency of stimulus 
outcome pairings’. This, coupled with the possible 
greater efficacy of JWH-018 at CB1 receptors, could be 
associated with a greater dependence liability for these 
synthetic cannabinoid receptor agonists when compared 
to Δ9-THC.
In rhesus monkeys, cross-tolerance was observed after 3 
days of Δ9-THC treatment for Δ9-THC but not for JWH-
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018 (Hruba et al., 2012). The greater loss of sensitivity to 
Δ9-THC relative to JWH-018 suggests that differences in 
CB1 receptor agonist efficacy are important in vivo and 
might underlie differences in the dependence liability 
and adverse effects of synthetic cannabinoid receptor 
agonists versus cannabis.
| B2. Human data
No studies were identified that have investigated the 
dependence and/or abuse potential of MDMB-CHMICA 
in humans.
The available information comes from:
 § A small case series of patients seeking medical 
treatment due to withdrawal symptoms following 
MDMB-CHMICA consumption;
 § Self-reported user experiences published in Internet 
drug discussion forums;
 § Comparison to studies regarding other synthetic 
cannabinoids.
Four cases of patients seeking medical treatment due to 
withdrawal symptoms following MDMB-CHMICA 
consumption were reported to the Poison Information 
Centre in Freiburg, Germany (Moosmann and Auwärter, 
2016, unpublished). In all 4 cases consumption of 
MDMB-CHMICA was analytically confirmed, but other 
substances were also detected (including THC-COOH, 
other synthetic cannabinoid receptor agonists, 
antidepressants and antipsychotic drugs). In one of the 
cases, the withdrawal symptoms were reported by 
a patient with a daily use of 3 grams of a commercial 
branded herbal mixture containing synthetic 
cannabinoid receptor agonists which included MDMB-
CHMICA. In two of the cases, withdrawal symptoms 
were reported following ‘regular’ consumption of herbal 
mixtures containing MDMB-CHMICA, which motivated 
the patients to seek medical help 1 to 2 weeks after the 
last use. The duration and extent of use was not reported 
for one case. A description of the withdrawal symptoms 
experienced by the patients was not reported.
A limited number of self-reported user experiences 
published in Internet drug user forums further suggest 
the substance may have dependence and abuse 
potential. These should to be interpreted with caution as 
it is not possible to confirm the specific substance(s) 
used, nor the purity, nor the dose/amount in respect to 
self-reported cases. Analyses of new psychoactive 
substances and the products containing them that are 
sold on the drug market have shown that the 
composition can differ between that claimed by the 
retailer, as well as vary over geographical areas and time. 
Furthermore, the users’ physical characteristics and 
health status are rarely reported. For these reasons, the 
information on user websites should be regarded as 
illustrative only and not taken as representative of users 
of MDMB-CHMICA in general.
Some users reported the existence of withdrawal effects 
from abstinence of MDMB-CHMICA. In one case, a user 
mentioned experiencing ‘[bad] cravings’ and reported 
a ‘numbing of the skin’, depression, anger and nausea (22). 
Other users report withdrawal symptoms which seem to 
last for longer periods (‘whole body went numb for 5 
days’) than expected with other synthetic cannabinoid 
receptor agonists (Castaneto et al., 2014). ‘Addiction’ to 
MDMB-CHMICA was reported by a user after 
consumption of ‘a couple of grams’ over ‘a few weeks’ 
(consumption ‘every two hours’).
Other synthetic cannabinoid receptor agonists have 
been previously found to produce withdrawal symptoms 
in humans. The literature in this regard has been 
systematically reviewed previously by Castaneto et al. 
(Castaneto et al., 2014). The authors found that whilst it 
was difficult to directly compare synthetic cannabinoid 
and cannabis, many of the symptoms are the same.
I Section C. Prevalence of use
|  Information from seizures, collected and biological samples
The formal notification of MDMB-CHMICA to the 
European Union Early Warning System (EU EWS) was in 
September 2014 by the Hungarian National Focal Point. 
The Reporting Form details a seizure of 0.19 grams of 
green/brown herbal product that was seized in August 
2014 by police in Ács, Hungary. Since then, the 
substance has been detected in 23 Member States, 
Turkey and Norway (23) (EMCDDA and Europol, 2016).
(22) Available at: https://drugs-forum.com/forum/showthread.
php?t=253270, accessed 13/06/2016
(23) ‘Detections’ is an all-encompassing term and may include seizures 
and/or collected and/or biological samples that are analytically 
confirmed. Seizure means a substance available (seized) through law 
enforcement activities (police, customs, border guards, etc.). 
Collected samples are those that are actively collected by drug 
monitoring systems (such as test purchases) for monitoring and 
research purposes. Biological samples are those from human body 
fluids (urine, blood, etc.) and/or specimens (tissues, hair, etc.) 
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Information from seizures
At the time of writing this report, 22 Member States 
(Austria, Belgium, Bulgaria, Croatia, Cyprus, Denmark, 
Estonia, Finland, France, Germany, Greece, Hungary, 
Latvia, Lithuania, Luxembourg, Netherlands, Poland, 
Romania, Spain, Sweden, Slovakia and the United 
Kingdom), Turkey and Norway had reported seizures (24) 
of MDMB-CHMICA to the EMCDDA and/or Europol.
Information reported to the EMCDDA and Europol 
indicates that over 120 kg of MDMB-CHMICA has been 
seized, as either herbal material or powder form.
Over 90% of the total number of seizures reported to the 
EMCDDA were in the form of herbal material (EMCDDA 
and Europol, 2016). This includes the seizure of a large 
number of commercial branded ‘legal high’ products.
The largest single bulk seizure reported to the EMCDDA 
was 40 kg of MDMB-CHMICA in powder form by 
Luxembourg, in December of 2014. The powder was 
contained in forty 1 kg packages and was seized at 
Luxembourg airport where it was in transit from 
Shanghai, China to Madrid, Spain (final destination).
Single seizures in excess of 1 kg were reported by five 
other countries: Germany (9.6 kg, herbal material 
containing also ADB-CHMINACA; 3.4 kg, herbal material 
containing only MDMB-CHMICA); Spain (4.8 kg, 
undefined physical form); Lithuania (4 kg, undefined 
physical form, purity 0.2%); Romania (2.9 kg, herbal 
material containing also 5F-MDMB-PINACA); and the 
Netherlands (over 1 kg of powder).
Information reported to Europol and the EMCDDA 
suggests that bulk powders of MDMB-CHMICA are 
imported from chemical companies based in China. 
These powders are then used to produce smoking 
mixtures within Europe.
Due to the high potency of some synthetic cannabinoid 
receptor agonists, the weight of powder needed for the 
herbal packet content can be in the order of a few tens of 
milligrams. This means that each kilogram of bulk 
powder may produce thousands of packets of ‘legal 
highs’.
The discovery of a large seizure suggests the 
involvement of organised crime in the distribution 
(24) Many ‘seizures’ relate to individual case-level data, however, some 
data provided to the EMCDDA are aggregated at the country level. 
Data is drawn from the Joint Report Questionnaires and data provided 
in the bi-annual data gathering (EU EWS progress and final reports) 
and from individual Reporting forms submitted on an ad hoc basis.
process. There are also indications of a significant 
internet retail trade within Europe, with customs and 
police making regular seizures of small quantities of 
these products.
Information from collected samples
A total of 4 Member States reported 60 samples that 
contained MDMB-CHMICA collected from users and 
purchased from bricks-and-mortar shops and online 
shops: Spain (3), France (2), Slovenia (2), and the United 
Kingdom (53). Some of the collected samples from 
users were linked to biological detections including 
serious adverse events (EMCDDA and Europol, 2016).
Information from biological samples
A total of 306 detections where MDMB-CHMICA was 
analytically confirmed in biological samples were 
reported by 7 Member States (Austria, Germany, 
Estonia, Hungary, Poland, Sweden, and the United 
Kingdom) and Norway. These include 53 serious adverse 
events (25 acute intoxications and 28 deaths). The 
remaining detections related to: intoxications reported to 
the Poisons Information Centres, persons suspected of 
driving under the influence of drugs, and persons 
suspected of having committed minor offences or 
crimes.
| Availability, supply, price
Data from seizures, collected samples and acute 
intoxications reported to the EMCDDA, as well as data 
from the EU ‘SPICE’ project (Moosmann and Auwärter, 
2016) suggest that MDMB-CHMICA is sold typically as 
commercial branded ‘legal high’ products in head shops 
as well as on the Internet. ‘Legal high’ products 
containing MDMB-CHMICA are marketed as ‘legal’ 
replacements to cannabis. As already mentioned, it is 
usually not stated if the ‘legal high’ product contains 
MDMB-CHMICA or any other particular synthetic 
cannabinoid therefore, it is reasonable to assume that 
the vast majority of users consume MDMB-CHMICA 
unknowingly.
MDMB-CHMICA is sold by online retailers either as 
commercial branded legal high products or as a powder 
which is advertised as a ‘research chemical’. In ‘legal 
high’ products it is not usually stated if the product 
contains MDMB-CHMICA or any other particular 
synthetic cannabinoid receptor agonist.
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Monitoring of online shops selling products containing 
synthetic cannabinoid receptor agonists provides some 
insight into the range of smoking mixtures available for 
purchase. Such monitoring, when combined with test 
purchasing of products for sale, is also a way of both 
keeping track of how the substances contained in 
a product change over time.
Detection in commercial branded ‘legal high’ 
products
Data obtained through the EU-funded projects ‘SPICE II 
Plus’ and ‘SPICE Profiling’ (25) suggests that MDMB-
CHMICA was commonly found in Germany in ‘legal high’ 
products being sold on the market, even though the 
representative nature of the samples analysed cannot be 
commented on (Moosmann and Auwärter, 2016, 
unpublished).
In the analysis of 532 products purchased on the 
Internet (Pütz et al., 2016), MDMB-CHMICA was the 
most commonly detected synthetic cannabinoid 
receptor agonist being detected in 31% of all products 
(166 products). MDMB-CHMICA was detected in 22% of 
all the herbal mixture products analysed between April 
2015 and April 2016 (116 products out of 532 test-
purchased from the internet) (Pütz et al., 2016).
Test purchase analysis of herbal mixture products has 
been conducted within EU-funded projects ‘SPICE II 
Plus’ and ‘SPICE Profiling’. In 2015, 427 ‘herbal mixtures’ 
were analysed, of which 186 samples (44%) contained 
MDMB-CHMICA. Of these 186 samples, 82% contained 
solely MDMB-CHMICA, 14% contained MDMB-CHMICA 
and one additional synthetic cannabinoid, and 4% 
contained MDMB-CHMICA and two additional synthetic 
cannabinoid receptor agonists (Moosmann and 
Auwärter, 2016, unpublished).
Within the Public Health Wales drug checking project 
WEDINOS (26), MDMB-CHMICA was detected in 36 herbal 
mixtures and in one powder sent for analysis (Moosmann 
& Auwärter, 2016; monitoring results between September 
2014 and February 2016) (see Section D1.2.1).
Detection in biological samples
See also sections D1.2.2 and D1.2.3.
(25) EU funded research project (2010 – 2012), continued by the “Spice II 
Plus” project aimed at ensuring a scientific knowledge base (including 
analytical libraries) on synthetic cannabinoid receptor agonists and 
other new psychoactive substances 
(26) Welsh Emerging Drugs and Identification of Novel Substances 
Between September 2014 and August 2015, MDMB-
CHMICA was detected in 14% of all serum samples 
tested in routine forensic work by the Institute of 
Forensic Medicine in Freiburg (Germany) (n=140 of 
a total of 1,046 samples analysed) (Angerer et al., 2016).
The IONA (27) project analysed samples of suspected 
NPS users who were at least 16 years of age presenting 
to participating hospitals in the United Kingdom with at 
least one defined feature of severe toxicity (Seywright et 
al., 2016). Out of 49 participants presenting in 7 hospital 
emergency departments, 7 individuals (14%) tested 
positive for MDMB-CHMICA.
A prospective observational cohort study (Abouchedid 
et al., 2016) enrolling adult patients who presented with 
acute recreational drug toxicity to the emergency 
department of 1 hospital in London (United Kingdom) 
found MDMB-CHMICA in 4% (n=7) of all recruited cases 
(n=149). Synthetic cannabinoid exposures represented 
12% (n=18) of the total caseload (n=149).
Finally, the EU-funded project Euro-DEN Plus analysed 
10,956 presentations to 16 sentinel centres in 10 
European countries in a two year period (October 2013 – 
September 2015). MDMB-CHMICA was found in only one 
case (in Munich, Germany). Synthetic cannabinoid 
receptor agonists were found for in less than 1% of all 
presentations (104 out of 10,956). Euro-DEN data are 
collected based on self-report, with analytical screening 
being carried out in approximately 15% of the cases (with 
methods varying according to the centre in question).
Availability from Internet vendors
Table 4 lists the results of an Internet search for online 
shops selling research chemicals in various countries 
(Belgium, Czech Republic, Germany, Hungary, The 
Netherlands, Poland, Spain, Sweden, United Kingdom, 
Canada, USA, China) which was conducted in March 
2016 (Moosmann and Auwärter, 2016, unpublished). 95 
shops were screened for their product portfolio. 28 
shops had MDMB-CHMICA listed on their website, of 
which two shops advertised the substance ‘MDMB-
CHMICA’ and 26 shops named it ‘MMB-CHMINACA’. In 6 
of the 28 shops the compound was listed as ‘out of 
stock’. The table also lists the price range for the 
compound depending on the quantity ordered.
MDMB-CHMICA was controlled in the People’s Republic of 
China in October 2015 and although some Chinese vendors 
still list MDMB-CHMICA on their webpage, it has been 
(27) Identification of Novel psychoActive Substances 
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reported that this compound is generally not shipped any 
longer (Moosmann & Auwärter, 2016, unpublished).
| Prevalence of use
No studies were identified that have investigated the 
prevalence of use of MDMB-CHMICA in the general 
population.
Prevalence of use of products containing synthetic 
cannabinoid receptor agonists
Information on the extent to which synthetic 
cannabinoid products are used is limited; however, 
knowledge of the situation is improving as more 
countries incorporate questions about their use in 
general population surveys. From the information that is 
available, it would appear that the prevalence of their use 
in the general population is low in Europe. A number of 
surveys aimed at examining the prevalence of use of 
‘Spice’-like products have been launched but their 
coverage and representativeness remains limited 
(EMCDDA, 2016).
A number of surveys in European countries report on the 
use of synthetic cannabinoid receptor agonists, although 
they are not comparable as they use different methods, 
sampling frames and terminology. Overall, these studies 
indicate generally low prevalence levels.
Over 50 % of B-samples submitted to the EU funded 
‘SPICE’ project from prisons are positive for synthetic 
cannabinoid receptor agonists.
The United Kingdom (England and Wales) asked about 
the use of ‘Spice’ in two consecutive household surveys 
and reported lifetime prevalence levels for adults 
(16–64) at 0.2 % in 2010/2011 and 0.1 % in 2011/2012 
(Smith and Flatley, 2011;Office for National Statistics, 
(28) Exchange rates used for calculation in €: 1 GBP = 1.30 €; 1 USD = 
0.90 €, 1 PLN = 0.23 €
2012). In the latest British Crime Survey for England and 
Wales covering 2014/2015 a total of 0.9 % of adults 
(16–59) had used new psychoactive substances in the 
last year, of which 61 % had used a herbal smoking 
mixture (Home Office, 2015). The question was not 
repeated in subsequent years due to the low prevalence 
rate.
In Spain a 2012 national survey on drug use among 
students aged 14–18 with a sample of 27 503 also 
identified low levels of use of ‘Spice’ products, with 
prevalence rates of 1.4 % for lifetime use, 1.0 % for last 
year use and 0.6 % for last month use, which indicated 
a small increase from the previous survey results from 
2010 (1.1 %; 0.8 %; and 0.5 % respectively) (Spanish 
Observatory on Drugs, 2012). This compares with 0.5 %, 
0.1 % and 0 % in a more general Spanish survey of 15- to 
64-year-olds conducted in 2013 (Spanish Observatory 
on Drugs, 2013).
In France in 2014 a survey of adults (18–64) with 
a question about the use of ‘synthetic cannabinoids’ 
reported lifetime use of 1.7 %. First-time users of these 
new synthetic products are mostly males (2.3 % vs. 1.2 
% of females) and from the youngest generation (under 
35 years): 4.0 % of 18- to 34-year-olds had tried 
synthetic cannabinoid compared to 0.6 % of 35- to 
64-year-olds (Beck et al., 2015). Another survey in 
France, among young people aged 17, reported that 1.7 
% of them have previously used a synthetic cannabinoid 
(Spilka et al., 2015).
The German city of Frankfurt has studied the use of 
smoking mixtures and ‘Spice’ among students aged 
15–18. They reported lifetime levels of use of 7 % in 
2009; 9 % in 2010; and 7 % in 2011 and 2012 (Werse et 
al., 2011; Werse et al., 2012; Bernard et al., 2013). In 
2013 lifetime use of smoking mixtures fell to 5 %, and 
although it increased to 6 % in 2014 it was still below the 
values from 2009–12 (Werse et al., 2014; Werse et al., 
2015). Students reporting the consumption of ‘Spice’ 
were, for the most part, experienced cannabis 
consumers.
TABLE 4
Online prices of MDMB-CHMICA depending on the order quantity (43)
1 g 10 g 100 g 1,000 g
Number of products 16 20 19 16
Range 8.50 – 23.40 € 60.00 – 203.40 € 405 – 770 € 1,620 – 6,100 €
Median 13.90 € 97.50 € 545 € 3,600 €
Mean 14.93 € 98.43 € 556 € 3,505 €
Mean (per gram) 14,93 € 9,84 € 5,56 € 3,50 €
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Finally, a number of studies among particular groups 
(clubbers, internet users, etc.) with non-probabilistic 
samples have generally identified higher levels of 
synthetic cannabinoid use than among the general 
population. The 2012 Global Drug Survey, for example, 
reported last year prevalence levels of 3.3 % among all 
UK respondents (not representative of the general 
population) and 5.0 % among UK regular clubbers 
(Guardian/Mixmag Survey, 2012).
There are notable differences between the prevalence of 
use of synthetic cannabinoid products between the 
European and US drug markets. The 2014 US Monitoring 
the Future survey of students suggests use is declining, 
with last year prevalence for 17- to 18-year-olds of 5.8 % 
in 2014, down from 7.9 % in 2013 and 11.3 % in 2012 
(National Institute on Drug Abuse, 2014).
I Section D. Health risks
| D1. Acute health effects
D1.1. Animal data
No studies were identified examining the acute toxicity 
of MDMB-CHMICA and/or its metabolites in animals.
D1.2. Human data
No clinical studies were identified that have examined 
the acute health effects of MDMB-CHMICA and/or its 
metabolites in humans.
In vitro data on cytotoxicity and genotoxicity is available 
for other structurally distinct synthetic cannabinoid 
receptor agonists (Koller et al., 2013a; Koller et al., 
2013b; Koller et al., 2015; Ferk et al., 2016).
Data from serious adverse events associated with 
MDMB-CHMICA are discussed in section D.1.2.2. Based 
on the data reported, the clinical features presented in 
cases of intoxication involving MDMB-CHMICA appear 
to be broadly similar to those found with other synthetic 
cannabinoid receptor agonists (Hermanns-Clausen et 
al., 2013; Pant et al., 2012; Papanti et al., 2013). These 
include: tachycardia, agitation, hallucinations, vomiting, 
chest pain, seizures, myoclonus, extreme anxiety leading 
to panic attacks and acute psychosis.
D1.2.1. User reports
There are limited user reports discussing MDMB-
CHMICA in Internet drug discussion forums. It is likely 
that this is because MDMB-CHMICA is sold mostly as 
commercial branded ‘legal-high’ products with little or 
no indication of the ingredients and therefore users may 
be unaware that they are taking MDMB-CHMICA. The 
few available user reports should be interpreted with 
caution, as discussed in section B2.
Self-reported users of MDMB-CHMICA describe it as 
a ‘potent’ compound. Several describe their experience 
with MDMB-CHMICA as unpleasant, and some mention 
having to resort to medical emergency services following 
consumption.
Some users report that the effects of MDMB-CHMICA 
are comparable to the effects of cannabis, with a more 
pronounced euphoria (see Section A3).
The most common effects reported by users in 
a systematic review that analyses 36 reports from 
MDMB-CHMICA users on internet discussion forums 
(Dargan et al., 2016b, unpublished) are presented in 
Table 5.
Some users report difficulties in dosing their 
consumption of MDMB-CHMICA, in that frequently the 
user may only realise that a ‘large’ dose was taken after 
the first effects are felt. When mentioned, onset is 
reported to occur between 0 to 3 minutes and last 
between 1 hour to 4 hours. This is in agreement with 
data presented in section D1.2.2. which suggests an 
average onset of action at 2.6 minutes and an average 
duration of effects of 2.6 hours.
In more than one case, longer term effects were 
described. One user reported ‘terrible dissociation, panic 
attacks and severe concentration issues over weeks’ and 
another one experienced withdrawal symptoms where 
the ‘whole body went numb for 5 days, I thought I was 
having a stroke’. These statements are consistent with 
data from serious adverse events where some 
individuals where kept in hospital care for up to 9 days 
following MDMB-CHMICA exposure (section D.1.2.2.).
Doses are described from 0.1 mg to 15 mg of MDMB-
CHMICA typically mixed in herbal media and 2 mg to 20 
mg of pre-prepared herbal material. In most cases the 
dose is described as ‘too much’, even for users who 
describe themselves as ‘tolerant’ (see Section A1.3).
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D1.2.2. MDMB-CHMICA associated acute toxicity
Acute intoxications reported by the Member States
42 acute intoxications associated with MDMB-CHMICA 
were reported by 7 countries: Austria (7 cases), France 
(2), Germany (7), Poland (3), Spain (2), Sweden (10), and 
the United Kingdom (11). These typically relate to acute 
non-fatal presentations to hospital emergency 
departments. The acute intoxications occurred during 
2014 and 2015.
In 25 of the 42 cases, MDMB-CHMICA was analytically 
confirmed in one or more biological samples taken from 
the patient at or around the time of intoxication: Austria 
(7 cases), Germany (3), Sweden (6) and the United 
Kingdom (9). The remaining 17 cases were excluded 
from the analysis (29).
Demographics
Of the 25 analytically confirmed acute intoxications, 17 
(68%) were male; 6 (24%) were female; in 2 (8%) of the 
cases the gender of the patient was unknown. The mean 
(29) In the remaining cases confirmation was either not obtained, not 
reported or made through an epidemiologically linked sample (for 
example, a sample collected from the patient found to contain 
MDMB-CHMICA).
age of the male cases for which an age was known was 
26 years (median 21); for the female cases the mean age 
was 25 years (median 20). For all cases, the ages ranged 
between 15 and 50 years old.
Substances analytically identified in biological samples
In 6 of the 25 analytically confirmed cases, MDMB-
CHMICA was the only substance identified. In the 
remaining 19 cases MDMB-CHMICA was detected along 
with other substances (30). These were typically other 
cannabinoids (including THC and its metabolites) (17 out 
of 25 cases) and/or ethanol (6/25). Other substances 
detected included methamphetamine (4/25), 
amphetamine (3/25) benzodiazepines (3/25) (31), 
morphine (1/25), and buprenorphine (1/25).
Seriousness of the intoxications
Data on the seriousness of the intoxication were 
reported for 13 out of the 25 analytically confirmed 
acute intoxications:
(30) In section 3.4.1 of the EMCDDA-Europol Joint Report on MDMB-
CHMICA information is provided on 25 analytically confirmed acute 
intoxications, 3 of which were mono-intoxications. Since the drafting 
of the Joint Report, further reporting has clarified that MDMB-CHMICA 
was the only substance found in a further 3 cases.
(31) In all 3 cases, no benzodiazepines were prescribed or used in the 
treatment of these individuals. The benzodiazepines found were 
considered to be due to illicit consumption.
TABLE 5
Most commonly reported effects related to use of MDMB-CHMICA (Dargan et al., 2016b, unpublished).
Theme Effect Number of Reports %
Total Number of Reports 36
Physiological Palpitations 11 30.6%
Nausea & Vomiting 9 25.0%
Loss of Consciousness 6 16.7%
Chest Pain 5 13.9%
Sedation 4 11.1%
Red Eyes 2 5.6%
Mental State Euphoria 11 30.6%
Visual hallucinations 6 16.7%
Anxiety 5 13.9%
Paranoia 4 11.1%
Retrograde amnesia 3 8.3%
Sense of Doom 2 5.6%
Auditory Hallucinations 2 5.6%
Drug-related Tolerance 3 8.3%
Withdrawal Related Numbness 4 11.1%
Vomiting 2 5.6%
Depression 2 5.6%
Anorexia 2 5.6%
Insomnia 2 5.6%
Annex 1
RISK ASSESSMENTS | MDMB-CHMICA  
35/51
 § In 8 out of the 13 cases the seriousness of the 
intoxication was classified as life threatening. In all 8 
cases MDMB-CHMICA was not the only substance 
found. At least 4 of those cases were treated in 
hospital (no information on hospitalisation for the 
remaining 4 individuals);
 § In 3 out of the 13 cases the intoxication was classified 
as non-life threatening but required treatment in 
hospital;
 § In 2 out of the 13 cases no information was reported 
on whether the intoxication was life-threatening but 
both patients were found unconscious and required 
treatment in hospital.
Information on the length of hospital stay was available 
for 9 out of 25 cases. The hospitalisation period varied 
between 3 hours to 24 hours (mean: 12 hours; median: 8 
hours). In the work published by Hill and co-workers (Hill 
et al., 2016) the length of hospital stay of patients 
exposed to MDMB-CHMICA varied between 5 hours to 
22 hours (32) (n=6; mean: 14 hours; median: 15 hours).
Clinical features
Data on clinical features related to the 25 acute 
intoxications (including the 6 cases where MDMB-
CHMICA was the only substance detected) were 
generally consistent with those associated with 
intoxication by MDMB-CHMICA reported in the literature 
(Hill et al., 2016; Seywright et al., 2016; Angerer et. al, 
2016) (33) and with intoxication by other synthetic 
cannabinoid receptor agonists (Tait et. al, 2016).
Coma and unconsciousness was the most prevalent 
feature, having been reported for 10 out of 25 cases. 
Other clinical features reported were: tachycardia (7 
cases), syncope (6), hyperemesis and/or nausea (4), 
mydriasis (3), seizures and convulsions (2), bradycardia 
(2), somnolence (2), serotonin toxicity (2), urinary and 
faecal incontinence (1), respiratory acidosis (1), 
metabolic acidosis (1). These included (but are not 
limited to): confusion, agitation, aggressiveness, 
changes in mood, hallucinations, tachycardia, mydriasis, 
hyperemesis, and unresponsiveness.
In 4 out of 25 cases the patients were described as 
exhibiting aggression and/or severe disturbance of 
behaviour, some of which resulted in police intervention 
and/or transfers to psychiatric units.
(32) One (atypical) case was not included in this analysis. The patient in 
question had been exposed to MDMB-CHMICA and methiopropamine 
and the hospitalisation was prolonged for 189 hours (ca. 8 days).
(33) The 9 reports of acute intoxications with MDMB-CHMICA published by 
Seywright and co-workers (Seywright et al., 2016) may be duplicates 
of cases reported to the EMCDDA.
Route of administration and physical form of the 
substance/product
Data on the route of administration was available for 14 
out of 25 cases. In all of them, the substance was 
smoked, presumably smoked or inhaled. The substance 
was consumed as a herbal product in all cases (8 cases) 
for which information about the physical form of the 
substance was available.
Acute intoxications identified from open source 
information and other sources
30 cases of individuals seeking medical assistance 
following consumption of MDMB-CHMICA were 
registered by the Poisons Information Centre in Freiburg, 
Germany, between 2014 and 2015 (Moosmann and 
Auwärter, 2016, unpublished) (34). All cases were 
analytically confirmed from biological samples taken 
from the patients. 12 out of 30 cases were considered 
mono-intoxications because all other serum findings 
were considered either not relevant (e.g. low levels of 
THC-COOH) or resulting from hospital treatment (e.g. 
benzodiazepines). The clinical features reported for the 
cases of mono-intoxications were in agreement with the 
data already discussed and included: drowsiness or 
somnolence, tachycardia, vomiting and nausea, seizures, 
syncope and behavioural disturbances such as 
aggression, panic, agitation and disorientation.
Two case series of patients exposed to MDMB-CHMICA 
presenting to hospital with acute intoxications were 
published by Hill et al. (Hill et al., 2016; n=7) and 
Seywright et al. (Seywright et al., 2016; n=9) (35). Clinical 
features of acute intoxications from these datasets 
appear to be similar with the clinical features of the cases 
reported to the EMCDDA. The demographic data of both 
cohorts was also comparable to the case-level data 
reported to the EMCDDA (n=16, 87.5% males, 12.5% 
females, ages between 15 and 57 years old). Duration of 
the hospitalization ranged from 3 to 24 hours (mean: 13h, 
median: 17h, n=15). Recovery occurred within 24 hours 
except one case (Hill et al., 2016), where 
methiopropamine was also detected, in which the patient 
was discharged after 9 days (36).
Both studies collected information on a number of 
clinical features which included body temperature. 
(34) It is possible that some cases may be duplicates of cases published 
by Angerer and co-workers (Angerer et al., 2016), as well as with data 
reported to the EMCDDA.
(35) As has been mentioned before, the 9 reports of acute intoxications 
with MDMB-CHMICA published by Seywright and co-workers 
(Seywright et al., 2016) may be duplicates of cases reported to the 
EMCDDA by the United Kingdom.
(36) This case has not been included in the analysis of duration of 
hospitalization.
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Hypothermia was observed in at least 50% of the cases 
(n=8 out of 16) (Seywright et al., 2016).
Hypoglycaemia was also discussed as resulting from 
exposure to MDMB-CHMICA. In one study (Seywright et 
al., 2016), 75% of the cases (n=7 out of 9) exhibited 
blood glucose concentrations indicative of fasting. Poor 
self-care from the users is admitted as a confounding 
factor but the association between MDMB-CHMICA 
exposure and hypoglycaemia is further supported by 
details of one of the cases. Here, a patient suffered from 
episodes of acute hypoglycaemia following consumption 
of the substance whilst in hospital and whilst being 
treated with a dextrose infusion. Previous studies with 
synthetic cannabinoid receptor agonists have linked 
exposure to the substances to hyperglycaemia rather 
than hypoglyceamia (Seely et al., 2011; Hess et al., 
2015).
In the 3 cases analysed by Hill and co-workers (Hill et al., 
2016) where MDMB-CHMICA was the only substance 
found, respiratory acidosis and respiratory depression 
evidenced by hypercapnia was reported. All the 
individuals for which information is available (5 out of 7) 
reported smoking as a route of administration.
Where measured (Seywright et al., 2016), concentration 
of MDMB-CHMICA in blood ranged from less than 1 to 
22 ng/ml (mean: 5 ng/ml, median: 2 ng/ml, n=9). No 
positive correlation was found between MDMB-CHMICA 
concentration and toxicity features displayed by the 
patients.
Recent work by Angerer et al. (Angerer et al., 2016) 
further suggests that the ‘severity of intoxication cannot 
be directly correlated with serum concentrations’ of 
MDMB-CHMICA. In a case series of 7 individuals with 
positive serum findings of MDMB-CHMICA (37), higher 
serum concentration was not associated with more 
severe symptoms. Furthermore, high serum 
concentrations can be expected in frequent users 
without necessarily leading to acute toxicity.
The series comprised of:
 § 3 acute (mono) intoxications which required 
hospitalisation (38) where MDMB-CHMICA serum 
concentrations varied between 0.1 ng/mL to 2.0 ng/
mL;
(37) It is possible that some cases may be duplicates of cases published 
by Moosmann and Auwärter (Moosmann and Auwärter, 2016, 
unpublished), as well as with data reported to the EMCDDA.
(38) The 3 reports of acute intoxications with MDMB-CHMICA published by 
Angerer and co-workers (Angerer et al., 2016) overlap with data 
reported to the EMCDDA by Germany. 
 § 2 cases of driving under the influence of drugs where 
MDMB-CHMICA serum concentration were 1.0 ng/
mL and 2.0 ng/mL;
 § 1 case for which no which no clinical features were 
reported and which did not required hospitalisation 
where MDMB-CHMICA serum concentration was 0.45 
ng/mL; and
 § 1 case of police arrest for which no clinical features 
were reported and which did not required 
hospitalisation but displayed the highest MDMB-
CHMICA serum concentration of the case series (91 
ng/mL).
A prospective observational cohort study of adult 
patients presenting to an emergency department in 
London during a period of 6 months in 2015 
(Abouchedid et al., 2016) found that at least 7 patients 
had been exposed to MDMB-CHMICA (0.08 – 8 ng/mL 
in blood) prior to being treated by emergency services. 
No further details are given about the cases.
1 case of acute monointoxication with MDMB-CHMICA 
was reported by Dargan et al. (Dargan et al., 2016) as 
part of the EURO-Den project. The individual in question 
(male, 30 years old) presented at a hospital in Germany 
following consumption of MDMB-CHMICA, which was 
analytically confirmed (serum: 0.94 ng/mL). He was 
agitated, psychotic and aggressive with hallucinations 
and had destroyed a room in his house; there was also 
a history of pre-hospital seizures. On arrival in the 
Emergency Department he was drowsy and tachycardic 
but other observations were normal including 
temperature (37.9 ºC) and blood pressure (118/61 
mmHg). He was admitted to intensive care and was 
sedated and intubated for ongoing agitation and 
aspiration pneumonia. He was in hospital for 9.5 days 
before discharging himself.
Lastly, WEDINOS has registered 14 cases of acute 
intoxications following exposure to MDMB-CHMICA. 
These were analytically confirmed from samples of the 
products used or believed to be used by the patients but 
not from biological samples. The cases were comprised 
of 71% males and 29% females (n=14) with ages 
between 19 and 38. All the individuals who reported 
a route of administration (13 out of 14) smoked MDMB-
CHMICA as an herbal mixture (purchased as 5F-AKB48 
in 2 out of 14 cases). Onset of adverse effects was 
reported to happen between 10 seconds and 5 minutes 
(n=10; mean: 2.6 minutes, median: 3.0 minutes) and 
duration of effects were self-reported between 45 
minutes to 10 hours (n=6; mean: 2.6 hours; median: 55 
minutes).
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D1.2.3. MDMB-CHMICA associated deaths
Deaths reported by the Member States
Case-level data for 29 deaths associated with MDMB-
CHMICA were reported by 5 Member States and 
Norway: Germany (5 cases), Hungary (3), Poland (1), 
Sweden (9), the United Kingdom (10), and Norway (1).
In 28 cases, MDMB-CHMICA was analytically confirmed 
in one or more biological samples taken from the 
decedents. In the remaining case MDMB-CHMICA was 
confirmed from a sample of the product believed to be 
used by the deceased, and this case has been excluded 
from the analysis.
Demographics
Of the 28 deaths, 24 were male (86%), 3 were female 
(11%) and the gender was not reported for one death (4 
%). The decedent’s ages ranged from 17 to 52 years old. 
The mean age of the male decedents was 32 years 
(median 33); the mean age of the female decedents was 
31 years (median 30).
Number of deaths by year
6 deaths occurred in 2014; 20 deaths occurred in 2015 
and 1 death occurred in 2016. The year of death was not 
known for 1 case.
Cause of death reported by the Member States
A review of the causes of death, which were reported for 
23 out of the 28 fatalities, found that:
 § In 1 case MDMB-CHMICA was reported to be the 
cause of death;
 § In 4 cases the information provided on the cause of 
death suggested that it was probably or possibly 
caused by MDMB-CHMICA;
 § In 6 cases MDMB-CHMICA was reported to have 
contributed to the cause of death;
 § In 2 cases the information provided on the cause of 
death suggested that MDMB-CHMICA probably or 
possibly contributed to the cause of death
 § In 2 cases the cause of death was reported as drug 
overdose or mixed intoxication;
 § In 8 cases an alternative cause of death was reported.
Circumstances of death
Information regarding the circumstances of death was 
reported for 18 out of 28 cases. For 72% of the cases, 
the individuals were found comatose or dead (at home or 
outside). In at least 2 of these cases smoking mixtures 
and smoking paraphernalia were found next to the body.
Deaths identified from open source information and 
other sources
10 deaths associated with MDMB-CHMICA exposure 
were identified in published scientific studies 
(Kronstrand et al., 2015; Westin et al.; 2015; Adamowicz 
et al., 2016; Seywright et al, 2016). All cases are 
duplicates of the cases reported to the EMCDDA by 
Member States.
The circumstances for a case series of 10 deaths which 
may be duplicates of cases reported to the EMCDDA 
that occurred between 2014 and 2015 (Moosmann and 
Auwärter, 2016, unpublished) are given below.
In one case MDMB-CHMICA was reported as the cause 
of death; in 3 other the substance was found to have 
contributed to the death. The remaining cases included 
mixed intoxications (with contribution from synthetic 
cannabinoid receptor agonists) (3 cases) or were 
attributed to other causes (3 cases).
In 6 out of 10 cases the decedents were found dead next 
to smoking paraphernalia. In these cases, the 
descriptions of the circumstances surrounding the 
decedent (location, position of the body, etc.) suggest 
that the deaths may have occurred shortly after 
consumption of the substance.
In one case, it is reported that the decedent smoked 1 
cigarette containing a herbal mixture after which he 
complained about nausea, began to gasp, and was not 
responsive to resuscitation attempts. MDMB-CHMICA 
and THC metabolites were found in the individual’s 
urine. This suggests the symptoms of intoxication were 
felt in a sudden manner.
Violent behaviour was reported in 1 case from this 
series.
As noted in section D1.2.2, correlation between the 
concentration of MDMB-CHMICA in biological samples 
and the severity of intoxication cannot be made. Some of 
the case reports show that the concentration of 
substance measured in asymptomatic users does not 
differ significantly from the concentration measured in 
cases of acute intoxications and/or deaths (Kronstrand 
et al., 2015). Angerer et al. (Angerer et al., 2016) 
emphasise that evaluation of death cases after use of 
synthetic cannabinoid receptor agonists should take into 
account all available information, including medical 
history, use of other drugs, preanalytical issues like 
post-mortem redistribution and possible tolerance.
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| D2. Chronic health effects
D2.1. Animal data
No studies were identified that have investigated the 
chronic health effects of MDMB-CHMICA in animals.
D2.2. Human data
No studies were identified that have investigated the 
chronic health effects of MDMB-CHMICA in humans.
| D3. Factors affecting public health risks
D3.1. Availability and quality of the new 
psychoactive substance on the market
MDMB-CHMICA is offered via the Internet either as 
powder (‘research chemical’) or in the form of ‘herbal 
mixtures’. In ‘herbal mixtures’ it is usually not stated if 
the product contains MDMB-CHMICA or any other 
synthetic cannabinoid. Furthermore, Germany reported 
to Europol that information from case reports associated 
with MDMB-CHMICA, indicates that this substance is 
well known among drug users and is quite often offered 
by drug dealers in addition to being available to purchase 
online (EMCDDA and Europol, 2016).
Data from seizures reported to the EMCDDA and to 
Europol indicate that bulk quantities of MDMB-CHMICA 
in powder have been imported into the EU from China 
(EMCDDA and Europol, 2016). In this respect, it is 
important to note that in October 2015 the People’s 
Republic of China controlled MDMB-CHMICA under 
national drug control legislation.
Information reported to the EMCDDA indicates that where 
MDMB-CHMICA has been detected with other substances, 
it has almost exclusively been detected in combination with 
other synthetic cannabinoid receptor agonists such as: 
ADB-CHMINACA, 5F-MDMB-PINACA, 5F-AMB (39), 
5F-AMBICA, AB-CHMINACA, 5F-AKB48, 5F-AMB-PINACA, 
and AB-FUBINACA (EMCDDA and Europol, 2016).
Information reported to Europol by Hungary regarding 
seizures of MDMB-CHMICA (EMCDDA and Europol, 
2016) stated that in 31% of all reported seizures 
(n=1257), MDMB-CHMICA was detected with other 
substances (EMCDDA and Europol, 2016) (see section 
A1.1). They reported that NPS frequently detected 
together with MDMB-CHMICA include: 5F-AMBICA (10% 
of seizures), 5F-AMB (5% of seizures) and AB-CHMINACA 
(4% of seizures). Furthermore, the purity of powder 
samples in five cases forensically analysed revealed very 
high concentrations of 95% or more of MDMB-CHMICA. 
Generally, the concentration of MDMB-CHMICA in herbal 
mixtures analysed in Hungary was established as ranging 
from 1 to 8%.
Additionally, Lithuania reported to Europol that the purity 
of a single seizure of 4 kg of MDMB-CHMICA was 
determined as 0.2%.
Regular market monitoring within the EU ‘SPICE’ 
projects including the analysis of 427 ‘herbal mixtures’ in 
2015 came to the result that 186 samples (44%) 
contained MDMB-CHMICA. Of these positive samples, 
82% contained solely MDMB-CHMICA, 14% MDMB-
CHMICA and one additional synthetic cannabinoid, 4% 
MDMB-CHMICA and two additional synthetic 
cannabinoid receptor agonists (Moosmann and 
Auwärter, 2016, unpublished) (see Section C).
In the analysis of 532 products purchased on the Internet 
between April 2015 and April 2016 (Pütz et al., 2016), 
MDMB-CHMICA was the cannabinoid most commonly 
found (detected in 166 products, 31%). 81% of the total 
number of herbal mixtures analysed (n=390) contained 
one substance, 16% contained two or more substances, 
and 3% contained no psychoactive substance. For the 
research chemicals analysed in the same study (n=60), 
in 65% of the products, labelling of the product was 
correct; in 6% of the products, labelling was partially 
correct; and in 29% of the cases labelling was wrong.
Within the Welsh drug checking project WEDINOS, 
MDMB-CHMICA was detected in 36 herbal mixtures and 
in one powder sent for analysis (Moosmann & Auwärter, 
2016; monitoring results between September 2014 and 
February 2016).
It should be noted that there can be considerable 
variability both within and between different batches of 
products sold under specific brand names, in terms of 
both the substances and the amount present, as it has 
been shown by various authors (Logan et al., 2012; Zuba 
and Byrska, 2013; Langer et al., 2014). Both high intra- as 
well as inter-package variabilities were observed for 
many synthetic cannabinoids (Choi et al., 2013).
MDMB-CHMICA content was analysed by Langer et al. in 
two herbal products. One product contained 82 mg/g 
MDMB-CHMICA and no further active ingredient. The 
second product contained 12 mg/g MDMB-CHMICA, 
89 mg/g AB-PINACA-5F and 66 mg/g AMB-5F (Langer 
et al., 2016).
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Analysis of 79 herbal mixtures containing MDMB-
CHMICA as the only active ingredient showed a range of 
content from 0.1% (w/w) to 11.1% (w/w). The median 
was 4.5% (w/w) and the mean 5.3% (w/w) (Moosmann 
and Auwärter, 2016, unpublished). It has to be noted that 
no homogenization was carried out prior to analysis to 
get an estimate of the doses actually consumed under 
realistic conditions (Pütz et al., 2016) (see Section C).
It should be noted that the manufacturing process can 
lead to an uneven distribution of the substances within 
the plant material. This may result in some products 
containing ‘hot pockets’ where the cannabinoid is highly 
concentrated, leading to doses that are higher than 
intended and increasing the risk of acute toxicity.
Furthermore, quite often more than one synthetic 
cannabinoid is added to ‘herbal mixtures’ (Moosmann et 
al., 2015). In this study, both interpackage and 
intrapackage content of synthetic cannabinoid receptor 
agonists variation were investigated by sampling without 
prior homogenization. The results showed that two joints 
of herbal mixture prepared from the same package could 
contain significantly different amounts of the active 
substance.
In Japan, Kikura-Hanajiri et al. (Kikura-Hanajiri et al., 
2013) detected an average number of 2.6 synthetic 
cannabinoid receptor agonists per product (Kikura-
Hanajiri et al., 2013). The maximum number of synthetic 
cannabinoid receptor agonists detected in one mixture 
by these authors was ten.
D3.2. Availability of the information, degree of 
knowledge and perceptions amongst users 
concerning the psychoactive substance and its 
effects
There is limited information on Internet drug discussion 
forums regarding the effects and potential health/
adverse effects related to the use of MDMB-CHMICA 
(Section D1.2.1).
D3.3. Characteristics and behaviour of users
Information on the characteristics and behaviour of 
users of MDMB-CHMICA is limited.
‘Legal high’ products containing MDMB-CHMICA are 
marketed as ‘legal’ replacements to cannabis. It is 
therefore likely that a range of different cannabis users 
would be interested in these products.
The available data suggests that MDMB-CHMICA is used 
by recreational users; by people who experiment with 
any drug that is new and readily available (such as 
‘psychonauts’); and by those who are regularly subjected 
to drug testing procedures (including those in prison).
MDMB-CHMICA might not be directly sought by users. 
Commercial branded legal high products are known to 
be highly variable in terms of composition and dosage 
and therefore users might not necessarily know that they 
are consuming MDMB-CHMICA.
D3.4. Nature and extent of health consequences
The limited information available on the pharmacology, 
dependence and abuse potential, and acute health 
effects of MDMB-CHMICA have been discussed above 
(Section A2, Section B, Section D1, Section D2).
Based on the available data, as well as self-reports and 
acute intoxications, the acute behavioural effects of 
MDMB-CHMICA, including effects on the ability to 
operate machinery and drive might bear some 
similarities to those induced by THC and by other 
synthetic cannabinoid receptor agonists such as 
JWH-018 and AM-2201.
Data related to cases of suspected driving under the 
influence of drugs were reported to the EMCDDA. There 
are insufficient data available to discuss the 
circumstances of these cases.
D3.5. Long-term consequences of use
There is no data regarding the long term consequences 
of using MDMB-CHMICA.
D3.6. Conditions under which the new 
psychoactive substance is obtained and used, 
including context-related effects and risks
There is very limited data on the conditions which 
MDMB-CHMICA is obtained and used.
Sources appear to include internet retailers, bricks-and-
mortar shops, friends and other acquaintances, and 
street level drug dealers (Section D3.1). In addition, the 
available data also supports the premise that some 
users are unaware that they have sourced and used 
MDMB-CHMICA (Section C and Section D1.2.1).
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The substance appears to be sourced by individuals that 
are seeking a replacement for cannabis (including users 
that need to pass drug-screening tests), by experimental 
drug users or ‘psychonauts’ that attempting to source 
the drug itself as well as others who seek synthetic 
cannabinoid legal-high type mixtures in a more generic 
sense, rather than individual compositions (Section 
D3.3, Section E6).
Based on the available data, it seems reasonable to 
consider that MDMB-CHMICA is used in the same 
environments as cannabis. Based on a limited dataset 
from serious adverse events, MDMB-CHMICA is used at 
home and to a lesser extent in recreational settings.
I Section E. Social Risks
| E1. Individual social risks
There is no data on the effects of MDMB-CHMICA on 
individual social risks.
| E2. Possible effects on direct social environment
There is no data on the possible effects of MDMB-
CHMICA on the direct social environment.
| E3. Possible effects on society as a whole
There is no specific data on the possible effects of 
MDMB-CHMICA on society as a whole.
| E4. Economic costs
There is no data on the effects of MDMB-CHMICA on 
economic costs.
Given the lack of data available on acute health 
emergencies and healthcare utilisation related to the use 
of MDMB-CHMICA, it is not possible at this time to 
estimate whether this substance is associated with 
greater healthcare costs than other drugs.
|  E5. Possible effects related to the cultural context, for example marginalisation
There is no specific data on the possible effects of 
MDMB-CHMICA related to the cultural context.
|  E6. Possible appeal of the new psychoactive substance to specific population groups within the general population
There is no specific data on the possible appeal of 
MDMB-CHMICA to specific population groups.
The available data suggests that MDMB-CHMICA is used 
by cannabis users. The extent of the possible appeal of 
synthetic cannabinoid receptor agonists to this group of 
users may be compounded by different factors, as users 
seem to be a heterogeneous group. They may include 
those wanting a legal alternative to illegal drugs, or drug 
users wishing to pass successfully an employment/other 
drug testing procedure aimed at detecting illicit drug use. 
This may be an important issue for any setting where 
drug abstinence control is obligatory (e.g. specific 
psychiatry or prison settings, driving liability testing, etc.).
I  Section F. Involvement of organised crime
|  F1. Evidence that criminal groups are systematically involved in production, trafficking and distribution for financial gain
No information has been received by Europol indicating 
production of MDMB-CHMICA within the EU.
Germany reported details on an investigation that led to 
the dismantling of a processing site, where herbal 
mixtures containing MDMB-CHMICA were prepared. 
Tablets mimicking ecstasy but containing different NPS 
were also detected during this investigation. In November 
2015, German police seized over 17 kilograms of herbal 
mixtures during a house search. Several small plastic bags 
containing different powders and tablets were also seized 
along with ingredients required for tableting: caffeine, 
other binding agents, coloured dyes, vitamin preparations 
and packaging units. An individual involved in the 
processing stated that he mixed the herbal material with 
the synthetic cannabinoid ‘MMB-CHMINACA’ (MDMB-
CHMICA) and then sold the mixtures via the internet.
Forensic analysis conducted as part of this investigation 
resulted in the following findings, specifically in relation 
to MDMB-CHMICA (39):
(39) Other NPS were also detected as part of this investigation into 
a processing site in Germany, including: synthetic cathinones i.e. 
4-CMC, buphedrone; arylalkylamines i.e. EAPB; and other synthetic 
cannabinoid receptor agonists i.e. ADB-CHMINACA. 
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 § 365.62 gram of herbal mixture: MDMB-CHMICA
 § 9612 gram of herbal mixture: MDMB-CHMICA and 
ADB-CHMINACA
German authorities stated that no direct links with 
organised crime groups (OCG) have been identified. 
However, they also state that easy access to MDMB-
CHMICA in smaller amounts via online vendors in and 
outside of the EU combined with access to bulk amounts 
via the Internet - mostly from wholesalers in China or 
other Asian countries, indicate at least a certain degree 
of organisation.
Hungary and Romania provided information in relation to 
the involvement of criminal groups in the processing, 
trafficking and distribution of MDMB-CHMICA.
Hungary and Romania indicated that criminal syndicates 
operating in their countries are responsible for tableting 
and/or processing sites (involving mixing and 
packaging), where NPS imported from China are 
prepared for final distribution via the Internet and/or 
through shipping companies. In one particular case 
investigated by the Romanian authorities, a criminal 
group imported NPS from China to Romania via the 
Czech Republic and Hungary. Members of this criminal 
organization were reported to be Hungarian nationals of 
Croatian origin.
Investigations conducted in the Member States and 
supported by Europol suggest that some Member States 
may be emerging as European hubs for receiving new 
psychoactive substances from source countries.
Information provided by Spain regarding a seizure of 
almost 5 kilograms of MDMB-CHMICA, where the final 
destination of this shipment was another unspecified EU 
Member State, may be noteworthy in this context. 
Additionally, the largest single seizure of MDMB-
CHMICA reported in Europe (40), had originated in China 
(Shanghai) but was actually en-route to Spain as the 
final destination.
|  F2. Impact on the production, trafficking and distribution of other substances, including existing psychoactive substances as well as new 
psychoactive substances
Based on the information available to the EMCDDA and 
Europol it does not appear that the production, 
trafficking and distribution of MDMB-CHMICA impacts 
(40) 40 kilograms in powder form seized in Luxembourg in 2014
on other existing psychoactive substances or new 
psychoactive substances.
|  F3. Evidence of the same groups of people being involved in different types of crime
No information has been received by Europol of 
evidence of the same groups of people being involved in 
different types of crime in connection with MDMB-
CHMICA.
|  F4. Impact of violence from criminal groups on society as a whole or on social groups or local communities (public order and safety)
No specific information has been received by Europol on 
incidents of violence in connection with MDMB-
CHMICA. However, Germany reported that use of 
MDMB-CHMICA has led to reported acts of violence and 
aggressive behaviour.
|  F5. Evidence of money laundering practices, or impact of organised crime on other socioeconomic factors in society
No specific information has been received by Europol on 
incidents of money laundering or impact of organised 
crime on other socio economic factors in society in 
connection with MDMB-CHMICA.
|  F6. Economic costs and consequences (evasion of taxes or duties, costs to the judicial system)
There are no published data to be able to determine the 
impact of MDMB-CHMICA in this area.
|  F7. Use of violence between or within criminal groups
There are no published data to be able to determine the 
impact of MDMB-CHMICA in this area.
|  F8. Evidence of strategies to prevent prosecution, for example through corruption or intimidation
There are no published data to be able to determine the 
impact of MDMB-CHMICA in this area.
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I Council Decision
COUNCIL IMPLEMENTING DECISION (EU) 2017/369 of 27 February 2017 on subjecting 
methyl 2-[[1-(cyclohexylmethyl)-1H-indole-3-carbonyl]amino]-3,3-dimethylbutanoate 
(MDMB-CHMICA) to control measures
THE COUNCIL OF THE EUROPEAN UNION,
Having regard to the Treaty on the Functioning of the European Union,
Having regard to Council Decision 2005/387/JHA of 10 May 2005 on the information 
exchange, risk-assessment and control of new psychoactive substances (1), and in particular 
Article 8(3) thereof,
Having regard to the proposal from the European Commission, 
Having regard to the opinion of the European Parliament (2), 
Whereas:
(1) A risk-assessment report on the new psychoactive substance methyl 
2-[[1-(cyclohexylmethyl)-1H-indole-3- carbonyl]amino]-3,3-dimethylbutanoate (MDMB-
CHMICA) was drawn up in accordance with Decision 2005/387/JHA by a special session of 
the extended Scientific Committee of the European Monitoring Centre for Drugs and Drug 
Addiction, and was subsequently submitted to the Commission and to the Council on 
28 July 2016.
(2) MDMB-CHMICA is classed as a synthetic cannabinoid receptor agonist. Synthetic 
cannabinoid receptor agonists, also referred to as synthetic cannabinoids, are a chemically 
diverse group of substances functionally similar to Δ9-tetrahydrocannabinol (Δ9-THC), the 
major psychoactive principle of cannabis. Δ9-THC and the synthetic cannabinoids naphtalen-
1-yl(1-pentyl-1H-indol-3-yl)methanone (JWH-018) and 1-(5-fluoropentyl)-1H-indol-3-yl]- 
(naphthalen-1-yl)-methanone (AM-2201) are cannabinoid receptor agonists controlled under 
the 1971 United Nations Convention on Psychotropic Substances.
(3) The high potency of MDMB-CHMICA and the highly variable amounts of the compound in 
‘legal high’ products constitute a high risk of acute toxicity.
(4) MDMB-CHMICA has been available on the drug market in the Union since at least August 
2014 and has been detected in 23 Member States. It is sold typically as commercial branded 
‘legal high’ products in head shops, as well as on the internet as a ‘legal’ replacement for 
cannabis. The available information suggests that bulk powders of MDMB-CHMICA are 
produced by chemical companies based in China. They are imported into the Union where 
they are either processed and packaged into commercial smoking mixtures or sold as 
powder. There is no information indicating production of MDMB-CHMICA within the Union.
(5) MDMB-CHMICA is typically administered by smoking a herbal mixture that is either from 
a ready-to-use commercial ‘legal high’ product or, less commonly, self-prepared. In 
commercial products it is usually not stated whether the product contains MDMB-CHMICA 
or any other synthetic cannabinoid receptor agonist. Therefore, many individuals exposed to 
MDMB-CHMICA might be unaware that they are using the substance. In addition, such 
consumers might be unaware of the dose that they are consuming. The manufacturing 
process can also lead to an uneven distribution of the substance within the plant material, 
(1) OJ L 127, 20.5.2005, p. 32.
(2) Opinion of 14 February 2017 (not yet published in the Official Journal).
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with the result that some products contain ‘hot pockets’ where cannabinoid is highly 
concentrated, increasing the risk of acute toxicity and outbreak of mass poisonings.
(6) The available data suggests that MDMB-CHMICA is used by cannabis users, 
‘psychonauts’ and those who are regularly subjected to drug-testing procedures, including 
those in prison.
(7) While there is no specific information on the possible effects of MDMB-CHMICA on the 
direct social environment or on society as a whole, multiple reports have indicated a 
possibility for violence and aggression as a consequence of its use. In addition, the detection 
of MDMB-CHMICA in cases of suspected driving under influence indicated a potential for 
wider risk to public safety.
(8) Eight Member States have reported a total of 28 deaths and 25 acute intoxications where 
MDMB-CHMICA was detected. If MDMB-CHMICA were to become more widely available 
and used, the implications for individual and public health could be significant.
(9) There is limited information to suggest the potential involvement of organised crime in the 
manufacture, distribution, trafficking and supply of MDMB-CHMICA within the Union.
(10) MDMB-CHMICA is not listed for control under the 1961 United Nations Single 
Convention on Narcotic Drugs or under the 1971 United Nations Convention on Psychotropic 
Substances. However, it is listed among the substances considered for review at the 38th 
WHO Expert Committee on Drug Dependence which makes recommendations to the United 
Nations Commission on Narcotic Drugs on the control measures that it considers 
appropriate.
(11) MDMB-CHMICA has no established or acknowledged human or veterinary medical use. 
Apart from its use in analytical reference materials and in scientific research investigating its 
chemistry, pharmacology and toxicology as a result of its emergence on the drug market, 
there is no indication that it is being used for other purposes.
(12) The risk-assessment report reveals that there is limited scientific evidence available on 
MDMB-CHMICA and points out that further research would be needed. However, the 
available evidence and information on the health and social risks that the substance poses 
provide sufficient grounds for subjecting MDMB-CHMICA to control measures across the 
Union.
(13) Given that 10 Member States control MDMB-CHMICA under national legislation in 
compliance with their obligations under the 1971 United Nations Convention on 
Psychotropic Substances and that five Member States use other legislative measures to 
control it, subjecting this substance to control measures across the Union would help avoid 
the emergence of obstacles in cross-border law enforcement and judicial cooperation, and 
would help protect from the risks that its availability and use could pose.
(14) Decision 2005/387/JHA confers upon the Council implementing powers with a view to 
giving a quick and expertise-based response at Union level to the emergence of new 
psychoactive substances detected and reported by the Member States, by subjecting those 
substances to control measures across the Union. As the conditions and procedure for 
triggering the exercise of such implementing powers have been met, an implementing 
decision should be adopted in order to put MDMB-CHMICA under control across the Union.
(15) Denmark is bound by Decision 2005/387/JHA and is therefore taking part in the 
adoption and application of this Decision, which implements Decision 2005/387/JHA.
Council Decision
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(16) Ireland is bound by Decision 2005/387/JHA and is therefore taking part in the adoption 
and application of this Decision, which implements Decision 2005/387/JHA.
(17) The United Kingdom is not bound by Decision 2005/387/JHA and is therefore not taking 
part in the adoption of this Decision, which implements Decision 2005/387/JHA, and is not 
bound by it or subject to its application,
HAS ADOPTED THIS DECISION:
Article 1
The new psychoactive substance methyl 2-[[1-(cyclohexylmethyl)-1H-indole-3-carbonyl]
amino]-3,3-dimethylbutanoate (MDMB-CHMICA) shall be subjected to control measures 
across the Union.
Article 2
As soon as possible, but no  later than by  4 March 2018, Member States shall take the  
necessary measures, in accordance with their national law, to subject the new psychoactive 
substance referred to in Article 1 to control measures and criminal penalties, as provided for 
under their legislation, in compliance with their obligations under the 1971 United Nations 
Convention on Psychotropic Substances.
Article 3
This Decision shall enter into force on the date following that of its publication in the Official 
Journal of the European Union.
This Decision shall apply in accordance with the Treaties.
Done at Brussels, 27 February 2017.
For the Council
The President
K. MIZZI
Council Decision
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Extended Scientific Committee
|  Prof. Dr Henk Garretsen, Faculty of Social and Behavioural Sciences, Tilburg University, Tilburg 
Co-chair of the risk assessment meeting
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Co-chair of the risk assessment meeting
|  Prof. Catherine Comiskey, Director, Centre for Practice and Healthcare Innovation, Trinity College 
Dublin
|  Dr Marina Davoli, Department of Epidemiology, Lazio Regional Health Service, Rome
|  Prof. Dr Gabriele Fischer, Medical University Vienna, Center of Public Health, Vienna
|  Prof. Dr Brice de Ruyver, Ghent University, Faculty of Law, Department of Criminal Law and 
Criminology, Ghent
|  Dr Simon Brandt, School of Pharmacy and Biomolecular Sciences, Liverpool John Moores 
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|  Prof. Félix Carvalho, Faculty of Pharmacy, University of Porto, Porto
|  Prof. Gaetano di Chiara, Department of Biomedical Sciences, University of Cagliari, Cagliari
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